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General Introduction 
General Introduction 
 
The studies presented in this thesis address how surveillance of respiratory 
syncytial virus (RSV) can be improved, investigate determinants of seasonal 
RSV activity, and assess diagnostic methods. In this introductory chapter, the 
background on respiratory illnesses and RSV in particular are described, as well 
as diagnostic and surveillance methods. Finally, the aim, relevance and outline 
of the thesis are presented. 
 
Acute Respiratory Illness 
Acute respiratory tract infections are the most common illness in all 
individuals: young children have about 4-8 respiratory tract episodes per year, 
for older children the incidence is slightly lower with 2-6 episodes per year.1 In 
persons older than twelve years of age respiratory illness also occur 
frequently, 37% of persons reported to have had respiratory tract symptoms in 
the last two months.2 
 
Acute respiratory tract infections frequently lead to consultation in general 
practice (GP). A substantial proportion of complaints (13%) in general practice 
concerns the respiratory tract and acute infection of the upper airways is with 
a prevalence of 57/1000 patients per year the second most common complaint 
presented to the general practitioner.2 The majority of respiratory infections 
affect the upper respiratory tract, and are mild, self-limiting viral upper 
respiratory tract infections (URTI).3 However, for lower respiratory tract 
infections (LRTI), each year about 3% of all children less than 1 year of age 
need to be admitted to hospital.4 The incidence of complaints concerning the 
respiratory tract, specified for URTI and LRTI by age group is presented in 
Figure 1.1.5 
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Figure 1.1: Incidence rates (per 1000) of GP-diagnosed upper respiratory tract 
infections (URTI) and lower respiratory tract infections (LRTI) 
according to age in years 
 
Source: Hak et al., Family Practice, 2006 
 
 
Respiratory disease causes a substantial burden on patients and their families. 
Also in terms of economical burden on society the costs are high due to 
consultations with doctors, direct medical costs, and the indirect costs of 
missed days from work or absences from school and day care.6,7 Costs 
attributable to respiratory tract infections in both outpatient and inpatient 
settings have an important impact on healthcare budgets. High risk groups to 
develop severe illness are the very young, immuno-compromised patients, 
patients with underlying chronic illness, and the elderly.8-12 
 
Aetiology of respiratory tract infections 
A great variety of viruses can cause respiratory tract disease, e.g. respiratory 
syncytial virus (RSV), influenza virus, parainfluenza virus, rhinovirus, 
coronavirus, and the human metapneumovirus. In addition, three new viruses 
have recently been discovered: human bocavirus, KI polyoma virus and WU 
polyomavirus.13-15 The aetiology of acute respiratory tract infections has been 
investigated in infants in the Netherlands. Rhinovirus was most frequently 
detected in cases, followed by RSV and coronavirus.16 
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Common respiratory viruses, virus family and estimated rates of hospitalisation 
are presented in Table 1.1. Other pathogens such as enteroviruses, 
adenoviruses and the bacteria Mycoplasma pneumoniae and Chlamydia 
pneumoniae can also cause respiratory symptoms and pneumonia. In this thesis 
we will mainly focus on RSV. 
 
 
Table 1.1: Common respiratory viruses and estimated hospitalisation rates 
for children below the age of five 
 
Pathogen Virus family Estimated rates of hospitalisation  
Respiratory syncytial virus  Paramyxoviridae 0.3-5.2/1000 children [17-19]  
Influenza virus Orthomyxoviridae 0.6-1.4/1000 children [17;18] 
Rhinovirus Picornaviridae 4.8/1000 children [20] 
Coronavirus Coronaviridae 0.6-2.2/1000 children [21;22]  
Parainfluenza virus Paramyxoviridae 1.2/1000 children [18]  
Human metapneumovirus Paramyxoviridae 1.3/1000 children [17] 
 
 
Clinical symptoms are somewhat similar for various respiratory pathogens and 
often include common cold and influenza-like symptoms (Table 1.2).23 
Therefore it is difficult to define the cause of illness when looking at clinical 
symptoms alone.24 The aetiology of respiratory disease can be assessed by 
laboratory testing. Hereby the relative burden of disease caused by the 
different respiratory pathogens can be better defined. It is important to 
determine the cause of illness by laboratory diagnosis, because it provides 
insight into the aetiology, specific treatment can be applied and preventive 
measures can be implemented. 
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Table 1.2: Common respiratory viruses and their associated clinical 
syndromes 
 
Respiratory virus Clinical manifestations Clinical complications 
Respiratory syncytial virus A feverish influenza-like illness 
with cough and wheeze 
Acute breathing difficulties 
Influenza virus Illness usually with fever, cough, 
sore throat, muscle pains 
Otitis media and 
pneumonia 
Rhinovirus Common cold Occasionally causes 
pneumonia 
Coronavirus Usually a mild form of influenza-
like illness 
Sinusitis and pneumonia 
Parainfluenza virus Wide range of symptoms ranging 
from common cold to croup 
Viral pneumonia and acute 
breathing difficulties 
Adenovirus Common cold symptoms with 
vomiting 
Can cause sinusitis and 
occasionally lead to 
pneumonia 
Source: Health Protection Agency. A Winter's Tale. 
 
 
Respiratory syncytial virus 
In 1956 a new virus was discovered in a chimpanzee with respiratory symptoms 
and it was named chimpanzee coryza agent.25 In the following decade the virus 
was renamed respiratory syncytial virus (RSV) to reflect the giant syncytia that 
were formed in tissue culture and has been known to be the most important 
viral pathogen of respiratory tract infection in infants and young children.26,27 
 
RSV is often introduced into the home by school-aged children who are 
infected with RSV and have a mild upper respiratory tract infection.28 Viral 
transmission occurs by direct inoculation of contagious secretions from the 
hands by large-particle aerosols into the eyes and nose, but rarely the mouth.29 
The prolonged survival of RSV on skin, cloth, and other objects emphasizes the 
importance of fomites in nosocomial spread.30 After an incubation period of 2-
8 days, RSV replicates in the nasopharyngeal epithelium, with spread to the 
lower respiratory tract one to three days later. The characteristic 
inflammation of RSV bronchiolitis is necrosis and sloughing of the epithelium in 
the small airways, with oedema, and increased secretion of mucus, which 
obstructs flow in the small airways.10  
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RSV is a single-stranded RNA virus. The genomic RNA is packaged in a shell of 
proteins, the nucleocapsid, which is surrounded by an outer envelope of the 
virus that consists of viral glycoproteins embedded in a lipid bilayer (Figure 
1.2). 
 
 
Figure 1.2: Schematic diagram of RSV, illustrating surface glycoproteins, lipid 
envelope and the nucleocapsid complex 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Smyth and Openshaw, Lancet 2006. 
 
 
There are two major groups of RSV strains, A and B, which are distinguished 
mainly by the variations within the G protein. The G (attachment) protein is 
important for viral attachment and release. The F (fusion) protein is important 
for viral attachment. Other structural proteins are the L (large polymerase 
complex) protein, P (phosphoprotein), N (nucleoprotein), M (matrix), SH (small 
hydrophobic) protein, and the small envelope (M2).10 
 
Epidemiology of RSV 
RSV is the most important viral pathogen in acute respiratory tract infections 
in children under 2 years of age. The infection rate of children aged less than 
12 months is estimated at 69/100 children, virtually all children have been 
infected by the age of 24 months and about half had experienced two 
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infections.32 The risk of re-infection is inversely related to the level of 
neutralizing antibodies in the serum and re-infection illnesses are generally 
mild.32 The spectrum of clinical disease ranges from mild upper respiratory 
tract illness, otitis media, croup, to apnoea in premature infants, pneumonia 
and bronchiolitis.33 In Europe, RSV accounts for 42-45% of hospital admissions 
for lower respiratory tract infections in children younger than two years of 
age, and inpatient populations tend to be younger and experience greater 
disease severity.34 For RSV bronchiolitis lengths of stay in European hospitals 
range from 4 to 10 days. Premature babies born at 30-35 weeks of gestation, 
infants with congenital heart disease, HIV-infected subjects, and patients on 
intensive immunosuppressive therapy are considered to be at risk of increased 
mortality and morbidity during RSV infection.12,35-37 It has been estimated that 
RSV causes about 500,000 deaths in children each year globally; while 
mortality due to RSV is very low in Western Europe, the number of child deaths 
due to acute respiratory infections worldwide is considerable with 70% of 
deaths occurring in Africa and Southeast Asia.38-39 
 
Many of the studies that assessed the relation between respiratory illness and 
viral pathogens include hospitalised children as subjects. This provides limited 
information on the overall epidemiology, as hospitalised children constitute 
the peak of the iceberg.40 The iceberg concept of infection is presented in 
Figure 1.3. 
 
Recognition of re-infection with RSV is confounded by the fact that other 
respiratory viruses cause similar clinical symptoms. The frequency of RSV re-
infections throughout life indicated that a large susceptible population is 
consistently available and that these usually mild re-infections are the primary 
source of serious infections in infants and those with underlying medical 
conditions.10 The clinical impact in certain adult populations is considerable 
and RSV can be an important cause of winter mortality.26 Those that are at 
increased risk for serious illness include adults with underlying 
cardiopulmonary disease, frail elderly persons, and the severe immuno-
compromised.9,42 RSV-related disease is often not recognized in elderly. This is 
probably due to the low awareness of RSV as cause of respiratory illness by the 
general practitioner and diagnostic testing is rarely performed. 
16 
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Figure 1.3: Iceberg concept of RSV infection, epidemiological distribution of 
RSV infection in young children 41 
 
Visit GP for acute  
bronchitis (5-6%) [2] 
Infection (100%) 
Hospitalisation (1%) 
Mortality (nihil / <0.01%) 
Intensive Care (0.1%) 
 
Source: Adapted from Bont, Caravisie 2004. 
 
 
RSV epidemic patterns differ by geographic location. In countries with 
temperate climates, such as the Netherlands, RSV causes yearly epidemics 
during late fall, winter and spring.43,44 In addition, a biannual pattern has been 
identified in some countries.45,46 RSV can circulate all year round in equatorial 
countries and appears regularly in tropical or semitropical countries, but with 
different patterns of seasonality.47 Epidemics frequently start in coastal areas 
or areas surrounded by water and then move to inland areas in the subsequent 
months.47 The seasonality of RSV epidemics may be partly explained by 
weather-related behaviour. For example indoor crowding occurs in wintertime 
and may impact epidemics. Additionally, the immunity of the at-risk 
population is important as well as the transmission capability of the virus 
under certain weather circumstances. 
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An overview of the main features of RSV are presented below.31  
 
Features of RSV infection: 
 
• Cause of worldwide annual epidemics 
• Infects almost all children by the age of two 
• Responsible for about 70% of cases of bronchiolitis in children 
• Causes coughs and cold in older children and adults 
• Causes re-infection despite the presence of serum antibody 
• The same serotype re-infects children and adults 
• Associated with recurrent wheeze for many years after bronchiolitis 
 
Source: Smyth and Openshaw. Lancet 2006 
 
 
Prevention and treatment 
At present, there is no licensed RSV vaccine. In the 1960s, a formalin-
inactivated RSV vaccine was given to infants and children.48 However, the 
vaccine did not protect against infection and was associated with an increased 
risk of severe RSV disease when some of the vaccinated children became 
naturally infected. A successful RSV vaccine should protect against 
bronchiolitis and pneumonia. However, it is unlikely that a RSV vaccine would 
protect against RSV infection because the naturally acquired immunity after 
RSV infection is neither complete nor persistent.49 Nevertheless, protection 
against severe disease develops after primary infection. Different vaccines are 
under preparation for different populations at risk.50,51  
 
Profylactic use of neutralizing antibody for high risk groups is available. 
Monthly administration of RSV hyperimmune globulin or monoclonal antibody 
against F protein (palivizumab) in premature infants or infants with chronic 
lung disease reduced the risk of subsequent hospitalisation for RSV infection.52 
Infants born with congenital heart disease are at risk for severe RSV infection, 
and palivizumab reduces RSV-related hospital admissions by about 45% in these 
children.53 Palivizumab is the first effective humanized monoclonal to be used 
to prevent infection. However the cost is high and although palivizumab 
reduces hospital admissions for serious RSV disease, its cost-effectiveness for 
infants born at more than 32 weeks of gestation is not proven. In 2009, the 
recommendations for use of palivizumab have been updated by the American 
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Academy of Pediatrics to ensure optimal balance of benefit and cost from this 
expensive intervention.54 Recently motavizumab, an enhanced-potency 
monoclonal antibody for the prevention of RSV has been evaluated. Pre-clinical 
data indicated that motavizumab has a much higher affinity for the F protein 
of RSV than palivizumab and is approximately 20-fold more potent than 
palivizumab in microneutralization studies.55 
 
Currently the only therapy for RSV infection is aerosolized or oral ribavirin, a 
broad-spectrum antiviral agent that is approved only for hospitalised infants. 
Trials of ribavirin for RSV lacked sufficient power to provide reliable estimates 
of the effects. The cumulative results of three small trials show that ribavirin 
may reduce the duration of mechanical ventilation and may reduce days of 
hospitalization. In addition, use of ribavirin may be associated with a decrease 
in the long-term incidence of recurrent wheezing following RSV disease.56 In 
practice, treatment of infants is generally limited to supportive care, including 
giving appropriate fluid replacement and oxygen.  
 
Furthermore, antibiotics are regularly prescribed for acute respiratory 
infections such as bronchiolitis, although these are not recommended unless 
there is concern about complications such as a secondary bacterial infection. 
No evidence was found to support the use of antibiotics for bronchiolitis.57,58  
 
Routine surveillance  
Many countries in Europe have developed systems for the reporting of 
infectious diseases. The aim of such reporting systems has always been to 
discover epidemic outbreaks of infectious disease quickly, and the rationale is 
that while one doctor might only see one or two cases of an epidemic, 
collective reporting at a regional or national level will make it possible to see 
the full picture.59 
 
Disease surveillance can be defined as the ongoing systematic collection and 
analysis of data and the timely dissemination of information to those who need 
to know so that action can be taken.60 The general principle of surveillance is 
that each country has a list of notifiable diseases; this disease is required by 
law to be reported to government authorities. 
 
One of the notifiable diseases that must be covered by the European 
Community Network for surveillance is influenza.61 National networks for the 
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surveillance of influenza have existed in Europe since the 1950s. In the late 
1980s, efforts were made to improve the clinical reports from sentinel 
physicians by integrating virological surveillance systems and by collecting data 
on a European level. The first European influenza surveillance project was the 
Eurosentinel scheme (1987-1991), this was followed by the ENS-CARE Influenza 
Early Warning Scheme (1992-1995, and the European Influenza Surveillance 
Scheme (1996-2008).62,63 One advantage of the European Influenza Surveillance 
Scheme is that RSV detections can also be reported in addition to influenza. 
 
Surveillance of respiratory infections can provide longitudinal data and can be 
used to help measure the impact of vaccines that decrease the burden of 
acute respiratory illness. For this purpose a vaccine surveillance network has 
been established in the United States for children from 0 to 4 years of age. 
Although there are currently no licensed RSV vaccines, effectiveness of RSV 
monoclonal antibody prophylaxis in high risk children could be evaluated with 
the data collected by this network.64 
 
Influenza virus and RSV infection are clinically indistinguishable and a 
substantial proportion of patients diagnosed with influenza-like illness are 
infected by RSV65 and influenza is detected in children with suspected RSV 
infection.66 Influenza causes winter epidemics and leads to hospitalisations and 
mortality.17,67 Patients with influenza A are more likely to present with fever, 
whereas patients with RSV will likely present with respiratory complaints and 
wheezing.66 Although RSV is not a notifiable disease in Europe it causes 
substantial morbidity in the population and is an important confounder in 
influenza surveillance, also because both RSV and influenza peak in 
wintertime. Therefore the report of RSV in addition to influenza is relevant. 
Surveillance data are increasingly used to monitor long-term trends or to make 
international comparisons.59 
 
Diagnosis 
Respiratory samples are obtained for diagnostic testing. There are several 
specimen types: throat swabs, nasal swabs, nasopharyngeal swabs, 
nasopharyngeal washes and nasopharyngeal aspirates. Conventional diagnostic 
methods include virus isolation, immunofluorescence and enzyme-linked 
immunosorbent assays that detect antigen. Viral culture in combination with 
immunofluorescence has been considered the “gold standard” for laboratory 
diagnosis. The last decade molecular techniques are increasingly used for the 
20 
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detection of respiratory pathogens and have become the “new gold standard” 
for the diagnosis in respiratory virus infections.68 Multiplex real-time PCR 
methods are more rapid and sensitive compared to the conventional 
methods.69,70 
 
The application of real-time PCR increases the sensitivity for respiratory viral 
diagnosis and results can be obtained within 6 hours, thus increasing clinical 
relevance.71 Rapid laboratory diagnostic investigation clearly is a prerequisite 
for effective antiviral treatment. Additionally, the laboratory testing is 
important to reduce the use of antibiotic in case of an uncomplicated viral 
infection. 
 
Children are known to shed RSV in high titres for up to several weeks, whereas 
shedding in adults and the elderly is presumed to be of relatively low titre and 
short duration.72 As a consequence conventional methods that are suitable for 
diagnosis in children lacks sensitivity in older patients.73 To overcome this lack 
of sensitivity real-time PCR methods can be used. For the frail elderly rapid 
antigen detection methods were found to be insensitive.73 Viral shedding may 
have occurred before the patients seek care. Moreover, clinicians have usually 
low suspicion for RSV infection in adult patients and this results in the 
infrequent use of diagnostic tests.10 In addition to the elderly, real-time PCR is 
also a sensitive method for the rapid diagnosis of RSV in immuno-compromised 
adults and represents a significant improvement over existing virus detection 
methods for this patient group.74 
 
Aim and relevance 
The aim of this thesis was to improve surveillance and diagnostic methods of 
respiratory syncytial virus (RSV) in Europe. We have investigated: 
a. which countries collect RSV data and whether these data are being reported 
timely, 
b. the occurrence of RSV and the relation with meteorological factors, 
c. what diagnostic methods are used to detect RSV, and 
d. what factors relate to the sensitivity of a diagnostic RSV test. 
 
With respiratory virus surveillance one can get insight into the occurrence of 
winter infections, what respiratory pathogen causes the illness, when is the 
peak and what is the effect of the winter infections on the population. 
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Respiratory tract infections are common. It is important to have a reliable 
report on the incidence of respiratory infections, preferably by age group, and 
the laboratory testing to identify the cause of respiratory infections. This 
information will provide directions for possible target groups for the 
development of vaccines, such as for RSV and para-influenza virus.  
 
Outline of this thesis 
Chapter 2 describes surveillance methods used in influenza reporting 
surveillance systems in Europe and investigates whether testing is performed 
for other respiratory viruses, including RSV. In Chapter 3 recommendations for 
surveillance of RSV are made and in Chapter 4 the progress over seven years in 
RSV surveillance is presented. In Chapter 5 the variation of respiratory 
syncytial virus and the relation with meteorological factors is presented. 
Chapter 6 and 7 focus on the diagnostic methods; in Chapter 6 the impact of 
laboratory characteristics on the molecular detection of respiratory syncytial 
virus is investigated and in Chapter 7 we investigate the sensitivity of 
nasopharyngeal aspirates and swabs with real-time polymerase chain reaction 
for the main respiratory pathogens of childhood. Finally, in Chapter 8, the 
results of the earlier chapters are summarised and discussed and the 
implications and recommendations for future research are formulated. 
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Abstract 
 
The European Influenza Surveillance Scheme (EISS) is based on an integrated 
clinical and virological surveillance model. To assess the comparability of 
virological data, a questionnaire was sent to participants in June 2002 
enquiring about specimen collection, laboratory diagnosis of influenza and 
tests for other respiratory infections. The results showed differences, but also 
uniformity in virological data collection methods. Similarities were reported 
for the specimen collection procedures; the type of swab and the transport 
conditions were comparable. The diagnostic methods were diverse; differences 
were seen in the (sub)typing methods, with PCR used most often in western 
countries. The findings will be helpful for the interpretation of virological data 
collected by sentinel physicians and for the creation of a Community Network 
of Reference Laboratories for Human Influenza in Europe. Important objectives 
of the Community Network include the harmonisation of virological methods 
and the application of quality assurance assessments for the national reference 
laboratories. 
 
 
Introduction 
 
Influenza is well recognised as an infectious disease that causes considerable 
morbidity and mortality in the human population.1,2 In addition, there is the 
ever-present threat of an influenza pandemic.3 In Europe, national influenza 
surveillance networks have been established since the 1950s. In the late 1980s, 
efforts were made to improve surveillance by integrating data on a European 
level through a number of collaborative projects that led to the European 
Influenza Surveillance Scheme (EISS). The basis of the scheme is combined 
clinical and virological surveillance of influenza in the general population. 
Sentinel physicians report cases of influenza-like illness (ILI) or acute 
respiratory infection (ARI) to a national data collection centre and obtain 
respiratory specimens from patients for laboratory testing.4,5  
 
With regard to the surveillance of infectious diseases such as influenza, the 
role of the European Union (EU) has become more important in recent years.6 
The surveillance of influenza is a key element of the European influenza 
pandemic preparedness plan. An important task of surveillance is the early 
detection of influenza and the characterisation of potential pandemic strains 
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from clinical specimens.7 To improve influenza surveillance in Europe, the EU 
has supported the creation of a Community Network of Reference Laboratories 
for Human Influenza7 to accomplish several tasks, including the co-ordination 
of methods employed by the Member States for the diagnosis of influenza. 
 
The European Scientific Working group on Influenza conducted an inventory in 
1996 on the laboratory diagnostic and surveillance methods in 24 European 
countries.8 This study showed that the techniques used in influenza 
surveillance were heterogeneous and the performance of virological 
surveillance was therefore difficult to compare between countries. The 
methods used for the virological surveillance of influenza may have changed 
since 1996 and we wanted to have an update of the methods currently used for 
the testing of sentinel respiratory specimens in Europe. In addition, we wanted 
to know whether tests were routinely performed for the detection of other 
respiratory pathogens besides influenza. The inventory aimed to determine the 
status of virological methods routinely used by sentinel influenza surveillance 
networks participating in EISS during the 2001-2002 season. 
 
 
Material and Methods 
 
A questionnaire on virological methods used for influenza diagnosis and 
surveillance was developed and sent electronically to all EISS collaborating 
surveillance networks in June 2002. People that were responsible for collecting 
virological data in each network were asked to complete the questionnaire. If 
a network had more than one reference laboratory, respondents were asked to 
complete a single questionnaire. Twenty-one networks participated in the 
study. 
 
The following topics were included in the questionnaire: specimen collection, 
laboratory diagnosis of influenza and tests for other respiratory infections in 
addition to influenza. The questions in the survey concerned data collected 
during the 2001-2002 influenza season. All 21 networks completed the 
questionnaire. Results based on sentinel data are presented for all networks 
except for Poland and Sweden. The results from Poland and Sweden are based 
on data from non-sentinel sources. 
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Table 2.1: Sentinel specimen collection and transport* 
 
Network Material collected by 
sentinel pysicians 
Transport medium Mode of 
Transport 
Temperature at 
transport(1) 
Delay of 
transport 
(hrs) 
Belgium Two nasal and one 
throat swab 
EMEM containing antibiotics 
+ fungizone 
Mail Ambient 24-48 
Czech Republic Nasopharyngeal swabs, 
blood(2) 
Special viral transport 
medium (NIC) 
Ambulance 4 oC 24 
Denmark Nasal swabs and 
aspirates 
Viral transport medium Mail Ambient 24-72 
England Nasal and throat swabs NK Mail, courier Ambient 48-120(3) 
France Nasal or throat swabs Medium containing 
penicillin, streptomycin and 
amphotericine B 
Mail Ambient 24-72 
Germany Throat swabs Virocult Mail Ambient(4) 24-72(5) 
Ireland Combined nasal and 
throat swabs 
Viral transport medium Mail NK 48 
Italy Throat swabs Virocult (MedicalWire, 
England) 
Mail, courier Ambient 24-120(5) 
Netherlands Nasal and throat swab GLY-medium+pimaricine Mail Ambient 24-48 
Northern Ireland Nasal and/or throat 
swabs 
PBS+pencicillin, 
streptomycin and 
amphotericin 
Mail, special 
delivery 
Ambient 24 
Norway Nasopharyngeal swabs Hanks’s Balanced salt 
solution containing bovine 
albumin, fungizone and 
penicillin 
Mail Ambient 24(-48) 
Poland Nasal and throat swabs Sterile PBS and antibiotics Courier 8oC 24-48 
Portugal Nasal swabs Virocult (MedicalWire MW 
950/974/975) 
Express mail Ambient 18-24 
Romania Nasal and throat swabs Tryptose phosphate broth 
with gelatine 
Mail, courier 4oC 24-72 
Scotland Nasal and throat swabs Guanidine based viral Lysis 
buffer 
Mail NK 24-48 
Slovak Republic Nasal and throat swabs 
(blood) 
Hanks’s Balanced salt 
solution or viruculture 
medium with BSA, 
antibiotics and antimycotics
Courier 4oC(6) 0-72 
Slovenia Nasal and throat swabs GIBCO EMEM medium Mail, courier Ambient(7) 
4oC(8) 
1-48 
Spain Nasal and throat swabs Saline solution +antibiotics Courier 4oC(6)  24 
Switzerland Combined nasal and 
throat swabs 
GLY-medium + antibiotics Mail Ambient 24-48 
Wales Nasal and throat swabs 
(blood) 
Medium containing minimal 
essential salts buffer and 
indicator solution 
Mail Ambient 24-72 
 
Abbreviations: NK = Not known; BSA = bovine serum albumin; EMEM = eagles minimum essential medium; GLY = 
glucose lactalbumin yeast; PBS = phosphate buffered saline, NIC = National Influenza Centre. 
* Sweden was not included in the table as it did not collect sentinel specimens and the techniques used at the 
24 laboratories performing influenza detection are too varied to be included in the table. 
1 Ambient means no control of temperature. 
2 Not regular. 
3 Majority arrives in 48 hours. 
4 Storage swab containments at ambient temperature, swabs kept at 4oC. 
5 Majority arrives in 24 hours. 
6 If possible. 
7 When transported by mail. 
8 When transported by courier.  
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Results 
 
Sentinel specimen collection and transport 
Information on specimen collection is presented in Table 2.1. Most networks 
(12/20) collect nasal as well as throat swabs. The remaining networks collect 
either nasopharyngeal, or nasal, or throat swabs. In addition, three networks 
collect blood samples and one network nasal aspirates. Transport of the swabs 
occurred by mail in 16 networks and by courier in seven networks. Some 
networks used special delivery (Northern Ireland) or ambulance (the Czech 
Republic) for the transport of the swabs. The temperature at transport was 
ambient in 13 networks and 4ºC in five networks. The viral transport medium 
meant to preserve virus viability used was diverse, but usually contained 
antibiotics to inhibit growth of other microorganisms. Scotland used a lysis 
buffer specifically developed for preservation of nucleic acid, and therefore 
only suitable for PCR. The time delay in transport of the material from the 
sentinel physician to the laboratory varied between 0-120 hours for all 
networks; most networks reported a delay of 24-48 hours. 
 
Methods used for sentinel virological surveillance 
The methods routinely used by the EISS networks to isolate or identify the 
influenza viruses in sentinel respiratory specimens are presented in Table 2.2. 
 
All but two networks (the Netherlands and Scotland) used culture on MDCK 
cells for the detection of influenza viruses. Seven networks used culture on 
embryonated chicken eggs, and five networks used other cell lines in addition 
to MDCK cells. Diverse rapid techniques for virus detection are used, with RT-
PCR most often used in the western countries and ELISA in the eastern 
countries. 
 
The delay between specimen collection and the test result for typing 
(determination of influenza A or B) and subtyping (determination of H subtype 
and occasionally the N subtype) is shown in Table 2.2. The delay was variable 
and differed between EISS networks. A comparison of the delay in typing and 
subtyping is difficult to make since a variety of methods were applied to 
determine the type and subtype. For example, by using subtype specific PCR 
assays typing and subtyping can be done directly on the clinical specimen, 
whereas when typing and subtyping a virus isolate, the time needed to grow 
the virus is the defining factor. 
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Table 2.2: Laboratory methods in Europe used for sentinel surveillance of 
influenza 
 
Virus detectionNetwork 
Virus isolation 
(culture) 
Rapid tests 
Typing (A/B) Typing delay 
(days)6 
Subtyping 
(H and/or N)7 
Subtyping 
delay 
(days)6 
West         
Belgium  MDCK Directigen Flu 
A+B 
 ELISA 1-3 PCR 14-21 
Denmark  MDCK ELISA, PCR  ELISA, PCR 5-10 HAI 14-21 
England  MDCK, MK PCR  HAI, ELISA, PCR, 
IF 
1-2 HAI, PCR 1-2 
France  MDCK ELISA  HAI, ELISA NK HAI, PCR1 NK 
Germany  MDCK PCR  PCR NK HAI2, PCR2 NK 
Ireland  MDCK PCR  PCR 2-7 PCR 2-14 
Italy  MDCK, CE PCR, dIF  HAI, PCR 2-10 HAI, PCR 2-10 
Netherlands  MK PCR  HAI 4-10 HAI 5-11 
Northern Ireland  MDCK, CE dIF  IF 1-2 PCR 1-3 
Norway  MDCK PCR  PCR, IF, HAI 2-7 PCR, IF, HAI 2-7 
Portugal  MDCK, CE PCR  PCR 3-4 PCR 3-4 
Scotland  Not done PCR  PCR 2-10 Not done 14-28 
Spain  MDCK, HEp-2 + 
human lung 
fibroblast3 
PCR  PCR 2-5 PCR, HAI 3-10 
Sweden  MDCK Not done  PCR, IF, HAI NK PCR, IF, HAI NK 
Switzerland  MDCK, LLC-
MK2, A549 
Not done  IF 7-9 PCR, HAI NK 
Wales  MDCK, MK dIF  IF 1-14 Not done 14-100 
East         
Czech Republic  MDCK, CE ELISA IPT4  ELISA, IPT 1 HAI 3-12 
Poland*  MDCK, CE5 dIF  HAI, IF 1-14 HAI 1-14 
Romania  MDCK, CE ELISA  HAI, ELISA 1-2 HAI, NI 2-6 
Slovak Republic  MDCK, CE ELISA, 
Directigen FIu 
A+B 
 HAI, ELISA 2-5 HAI 3-6 
Slovenia  MDCK, MK ELISA, PCR  PCR, IF 1-8 HAI NK 
 
Abbreviations: NK = Not known; MDCK = Madin-Darby canine kidney; MK = monkey-kidney; CE = chicken egg; 
ELISA = enzyme-linked immunosorbent assay; PCR = polymerase chain reaction; HAI = haemagglutination 
inhibition; (d)IF = (direct) immunofluorescence; NI = neuraminidase inhibition; A549 = human lung cancer cell 
line. 
* Data for Poland and Sweden are from non-sentinel surveillance systems. The Swedish responses to the typing 
procedures concern cultivated specimens sent by six virological laboratories to the Swedish Institute Desease 
Control. 
1 PCR is used for H1N2 subtyping. 
2 Method differs by laboratory. 
3 The HEp-2 cell line is an epithelial cancer cell line. 
4 Immunoperoxidase staining. 
5 For the 2002-2003 influenza season MDCK cells will be mainly used. 
6 Time between specimen collection and typing or subtyping. 
7 Networks were not asked to specify the methods used for subtyping H and N separately.  
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For typing of influenza viruses the following methods were applied: PCR (11 
networks), HAI (9 networks), IF (8 networks) and ELISA (7 networks). For 
subtyping the HAI assay was used in 15 networks. However, PCR was also used 
for subtyping in twelve networks. A total of nine networks applied more than 
one test to subtype influenza viruses. None of the five networks in eastern 
Europe used PCR, while 12 out of 14 networks that perform subtyping in 
western Europe used PCR (Table 2.2). Of these, eight networks used both HAI 
and PCR. 
 
Testing sentinel specimens for other respiratory infections 
Thirteen out of nineteen networks (the Czech Republic, England, France, 
Germany, the Netherlands, Northern Ireland, Portugal, Romania, Scotland, 
Slovenia, Spain, Switzerland, Wales) reported that they collect information on 
respiratory pathogens other than influenza virus in sentinel respiratory 
specimens. All thirteen networks collected information on respiratory syncytial 
virus (RSV), six networks collected data on adenovirus, five networks collected 
data on parainfluenzavirus and three networks collected data on rhinovirus. 
Three networks (England, the Netherlands and Slovenia) had information on 
other respiratory pathogens (e.g. coronavirus, Chlamydia pneumoniae, human 
metapneumovirus) (data not shown). Eleven networks reported that the 
sentinel swabs were tested for both influenza virus and RSV. 
 
 
Discussion 
 
The results highlight similarities in the specimen collection and transport 
procedures in the EISS networks. In most networks nose swabs as well as throat 
swabs were obtained and transported by mail to the laboratory. The laboratory 
methods used were heterogeneous, which confirms earlier findings.8 For virus 
culture, most networks used the same type of cells (MDCK), but for typing and 
subtyping of influenza viruses different methods (ELISA, HAI, PCR) were used. 
ELISA was more often used for typing and subtyping in eastern Europe and PCR 
was more frequently used in western Europe. Another important finding is that 
the majority of networks in EISS reported that they test sentinel swabs for 
other viruses (in particular RSV). 
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The type of respiratory specimen, the delay in the transport of swabs, the 
transport medium and the transport temperature are important factors that 
could potentially lead to an underestimation of the number of laboratory 
confirmed clinical cases of influenza reported by sentinel physicians. Our study 
has shown that most EISS networks used nose and/or throat swabs. In general, 
these are considered to be the right specimens for techniques such as culture 
and immunofluorescence.9 The transport of samples is advised at 4ºC or frozen 
at -70ºC.9 The outcome of our survey is that the specimens were often sent by 
post, at an ambient temperature and usually took 24-48 hours to reach the 
laboratory. This can be considered suboptimal, especially for virus culture. 
However, a study carried out in England and Wales found that clinical 
specimens sent by post provided good results when using multiplex RT-PCR 
techniques, although it is likely that there is some degradation of viral nucleic 
acid when specimens are transported this way.10 Another factor, the viral 
transport medium, should ideally include a balanced salt solution at neutral pH 
with protein stabilizers such as gelatine or bovine serum albumin (BSA) and 
antibiotics.9 The EISS networks used diverse media for the transportation of 
specimens, but in general these media met the mentioned demands. 
 
All but one network used virus isolation on cell culture as the primary method 
for the detection of influenza virus. This approach is commonly used as the 
EISS laboratories characterise their virus isolates and/or send material to the 
WHO Collaborating Centre at Mill Hill for strain characterisation, an activity 
that is very important to map the spread of influenza globally and to establish 
the influenza vaccines in the southern and northern hemispheres each season. 
The reasons for using additional techniques, like PCR and ELISA, for detection 
were confirmation of the results, increased sensitivity and the detection of 
other respiratory pathogens such as adenovirus (e.g. in Slovenia, Spain and 
Switzerland). 
 
The harmonisation of virological testing methods is an important objective of 
EISS. To initiate these efforts, a first Quality Control Assessment (QCA) was 
performed during the 2000-2001 season.11 Differences in virological results can 
be associated with the use of different laboratory techniques (e.g. PCR vs. cell 
culture10,12,13) or differences in the application of the same laboratory 
technique (e.g. PCR). The first QCA, carried out in 16 EISS laboratories, found 
that the sensitivity of the RT-PCR in Europe varied widely (40-100% for 
influenza, 71-86% for RSV), depending on the laboratory.11 A second QCA was 
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carried out during the 2002-2003 season and considerable improvements in the 
sensitivity rates were found (data not shown). The results of the first two 
QCAs, and QCAs planned in the future, will be used to further harmonise 
virological testing methods in EISS. 
 
The finding that sentinel specimens were being tested for other respiratory 
infections is important for EISS, as many agents are associated with clinical 
symptoms of influenza-like illness and acute respiratory infection. An 
important pathogen that contributes to this burden of disease is RSV; in terms 
of mortality the role of RSV is suggested to be even greater than influenza B 
and influenza A/H1N1.2 The results of the inventory indicated that a large 
proportion of the networks tested sentinel specimens for RSV and we could 
therefore collect more detailed information on RSV activity in Europe. These 
findings have led to the creation of an RSV Task Group to explore how the 
surveillance of RSV could be better developed and further integrated into EISS. 
 
In conclusion, sample collection and shipment are more or less similar whereas 
detection and (sub)typing methods are heterogeneous among the EISS 
networks. Despite this heterogeneity, results for detection and (sub)typing can 
be considerably improved when carefully controlled by external quality 
control, as the results of the two QCA studies showed. Further improvements 
may be made by a better harmonization and standardization of the applied 
methods. EISS will therefore take a number of actions within the framework of 
the recently created Community Network of Reference Laboratories for Human 
Influenza; these include the definition of basic tasks to be carried out by the 
laboratories, the preparation of standardised laboratory protocols and further 
QCAs. 
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Abstract 
 
Background 
Respiratory syncytial virus (RSV) is an important pathogen that can cause 
severe illness in infants and young children. In this study, we assessed whether 
data on RSV collected by the European Influenza Surveillance Scheme (EISS) 
could be used to build an RSV surveillance system in Europe. 
 
Methods 
Influenza and RSV data for the 2002-2003-winter were analysed for England, 
France, the Netherlands and Scotland. Data from sentinel physician networks 
and other sources, mainly hospitals, were collected. Respiratory specimens 
were tested for influenza and RSV mainly by virus culture and polymerase 
chain reaction amplification.  
 
Results 
Data on RSV were entered timely into the EISS database. RSV contributed 
noticeably to influenza-like illness: in England sentinel RSV detections were 
common in all age groups, but particularly in young children with 20 (40.8%) of 
the total number of sentinel swabs testing positive for RSV. Scotland and 
France also reported the highest percentages of RSV detections in the 0-4 year 
age group, respectively 10.3% (N=29) and 12.2% (N=426). In the Netherlands, 
RSV was detected in one person aged over 65 years.  
 
Conclusions 
We recommend that respiratory specimens collected in influenza surveillance 
are also tested systematically for RSV and emphasize the use of both 
community derived data and data from hospitals for RSV surveillance. RSV data 
from the EISS have been entered in a timely manner and we consider that the 
EISS model can be used to develop an RSV surveillance system equivalent to 
the influenza surveillance in Europe. 
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Background 
 
Respiratory syncytial virus (RSV) is the most important viral agent causing 
severe respiratory disease in infants and young children.1 Although infrequently 
recognised, RSV infection is common in adults and sometimes causes severe 
illness especially in the elderly.2,3 RSV infection presents with similar clinical 
symptoms to other respiratory viral infections, including influenza.4,5 Influenza 
is associated with increased general practice consultation rates6, increased 
hospital admissions7 and excess deaths. 7,8 RSV and influenza viruses frequently 
co-circulate around the same time of the year making it difficult to estimate 
their separate clinical impacts.9 The contribution of RSV to influenza-like 
illness needs to be assessed if this is to be used as a clinical endpoint for 
evaluating influenza vaccine effectiveness.10,11  
 
Advances in the development of RSV vaccines12 has prompted a need for 
research into the societal and economic impact of RSV infection in order to 
make sensible decisions about their potential use. So far, prevention of severe 
RSV-associated bronchiolitis has only been achieved in high-risk infants by 
passive administration of the humanized monoclonal antibody palivizumab. 13 A 
timely RSV surveillance system could be valuable in optimizing the use of 
palivizumab increasing its efficiency and reducing costs14 as doctors would 
become aware of the circulation of the virus and probable cause of illness in 
high-risk infants. 
 
Monitoring influenza activity has been coordinated by the European Influenza 
Surveillance Scheme (EISS) since 1996. EISS is one of the Designated 
Surveillance Networks established to monitor infectious diseases in the 
European Union.15 The surveillance is performed by sentinel primary care 
physicians and is based on an integrated clinical and virological surveillance 
model.16,17 In addition to the sentinel surveillance results on specimens 
obtained from other sources (mostly hospitals) are also reported. Currently, no 
integrated European surveillance such as the EISS is in place for RSV, although 
RSV surveillance initiatives have been reported by several EU Member States 
(Germany, the Netherlands, France, United Kingdom). 
 
We aimed to assess whether data already collected within EISS could be used 
to build an RSV surveillance system in Europe. We consider timeliness of RSV 
reports to EISS as well as the collection of both sentinel and hospital-based RSV 
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data by age group important for RSV surveillance. We analysed RSV and 
influenza virus reports in different age groups and study populations in four 
European countries, and we assessed whether RSV and influenza data were 
reported in a timely manner into the EISS database. 
 
 
Methods 
 
Influenza and RSV data available in the EISS database for the 2002-2003 winter 
(weeks 40/2002 to 20/2003) were analysed. Data from both sentinel 
practitioners and other sources (from hospitals, non-sentinel physicians, 
residential institutions) were used. Data from these other sources are referred 
to as non-sentinel in this paper. Four countries were included: England, 
France, the Netherlands and Scotland. Data for France was confined to nine 
regions in the south covering 37.5% of the French population. The selection of 
countries was based on the availability of both sentinel and non-sentinel 
virological data on RSV and influenza, and on a minimum number of 500 non-
sentinel respiratory specimens tested for RSV and/or influenza during the 
study winter. 
 
Specimen collection and analysis 
Combined nose and/or throat swabs were obtained from selected patients 
presenting to physicians in sentinel practices with influenza-like illness. In 
addition, general practitioners in Scotland were requested to sample patients 
with acute respiratory infections in the absence of patients presenting with 
influenza-like illness. The respiratory specimens were transported to 
participating laboratories mainly by regular mail.18 Similar laboratory methods 
were used in three out of four countries (Table 3.1); France used enzyme-
linked assays including ELISA (enzyme-linked immunosorbent assay) instead of 
RT-PCR (reverse transcriptase polymerase chain reaction).19 Although the 
sensitivity of ELISA has been reported to be lower than RT-PCR, ELISA is 
reliable for rapid laboratory diagnosis of influenza in infants and young 
children; for older patients application of virus isolation or RT-PCR is 
necessary.20 Samples were defined positive for RSV or influenza when at least 
one laboratory test yielded a positive result. 
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Table 3.1: Laboratory methods used for RSV and influenza virus detection or 
isolation 
 
 
 
Methods used for 
RSV detection/isolation 
Methods used for influenza virus 
detection/isolation 
England RT-PCR, culture RT-PCR, culture 
France  ELFA, culture ELISA, culture 
Netherlands RT-PCR, culture IF, RT-PCR, culture 
Scotland RT-PCR (multiplex)  RT-PCR (multiplex) 
 
ELFA: enzyme-linked fluorescent assay (automated qualitative test) 
ELISA: enzyme-linked immunosorbent assay 
IF: immunofluorescence; this technique was not performed for sentinel samples 
RT-PCR: reverse transcriptase polymerase chain reaction 
 
 
The sentinel networks in England and Scotland did not apply a precise case 
definition for influenza-like illness. The case definition used in France was: 
sudden onset of respiratory symptoms with infection context (fever, 
headaches), in the absence of other diagnosis. The case definition in the 
Netherlands contained the following criteria: an acute onset of illness 
(prodromal stage < 3-4 days), and at least one of the symptoms: coughing, 
rhinitis, sore throat, frontal headache, retrosternal pain, or myalgia.21 The 
selection of patients for swabbing was not based on pre-established diagnostic 
criteria. In France many samples were obtained from children because 
paediatricians as well as general practitioners are included in the surveillance 
network.22 Virological test results from sentinel practices were specified by 
age group (0-4, 5-14, 15-64, and over 65 years). Non-sentinel specimens 
obtained from hospitals were mostly examined for either RSV or influenza and 
not both viruses.  
 
Data analysis 
We examined the timeliness of RSV data entry into the EISS database by 
investigating whether data on RSV were included in the EISS Weekly Electronic 
Bulletin and compared this to the timeliness of influenza data. The Weekly 
Electronic Bulletin is published on the EISS website each Friday and reports the 
influenza activity for EISS member countries collected during the previous 
week. More details on the Weekly Electronic Bulletin can be found in the 
technical note.23 For the statistical analysis, the comparisons of percentages 
were performed using EpiTable in Epi Info version 6.04d (January 2001). 
Statistical significance was concluded if the p-value was < 0.05.  
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Results 
 
Respiratory Syncytial Virus 
RSV detections are summarized for each of the four countries in Table 3.2. For 
England RSV detections from sentinel practices were common in all age groups, 
but especially in young children aged 0-4 years with 40.8% (N=49) testing 
positive for RSV. The highest percentage RSV positive specimens was reported 
for the 0-4 age group in Scotland (10.3%, N=29) and France (12.2%, N=426) as 
well. In the Netherlands, RSV was detected in one person aged over 65 years. 
In England, the percentage of RSV positive reports (26.7%) was higher than that 
for influenza (21.3%; Chi2=3.9, p=0.048). Non-sentinel data (available by age 
group for England and Scotland only) showed that 92% or more of the RSV 
positive reports were obtained in children 0 to 4 years. 
 
Influenza 
Influenza virus detections are summarized in Table 3.3. Sentinel data indicated 
more influenza reports than RSV in Scotland, France and the Netherlands. The 
highest specimen positive proportions of influenza viruses were reported in 
children aged 5-14 years (England 52.4%; France 41.6%; Scotland 23.9%). Non-
sentinel data (available by age group for England and Scotland only) showed 
most confirmed influenza cases in the 0-4 and 15-64 age groups. 
 
Timeliness 
In each of the four countries sentinel and/or non-sentinel RSV data were 
entered in a timely manner, within 1-2 weeks after specimen collection, into 
the EISS database. A total of 26 Weekly Electronic Bulletins were published 
during the 2002-2003 winter season, from week 42 to week 15 of the following 
year. For the Netherlands, timely RSV data were not available for weeks 42-50 
because data entry only started that season. For the four countries data on 
influenza was reported for a total of 97 out of 104 weeks and RSV reports 
where made in a timely manner in 87 out of 104 weeks. 
 
 
47 
Chapter 3 
Table 3.2: RSV detections by country and age group for sentinel and non-
sentinel specimens. 
 
Country  Sentinel  Non-sentinel 
 Total number of 
specimens tested 
Number of 
specimens tested 
positive for RSV
Percentage 
positive (%)
Number of 
specimens tested 
positive for RSV 
England  
0-4 year 49 20 40.8 3,982 
5-14 year 63 16 25.4 13 
15-64 year 307 77 25.1 60 
> 65 year 45 13 28.9 11 
NK 11 1 9.1 85 
Total 475 127 26.7 4,151 
  
Scotland  
0-4 year 29 3 10.3 1,474 
5-14 year 67 0 - 24 
15-64 year 444 13 2.9 56 
> 65 year 58 3 5.1 19 
NK 15 
Total 598 19 3.2 1,588 
  
France  
0-4 year 426 52 12.2  
5-14 year 442 20 4.5  
15-64 year 557 14 2.5  
> 65 year 32 0 -   
Total 1,457 86 5.9 1,748 
  
Netherlands  
0-4 year 0 - -  
5-14 year 7 0 -  
15-64 year 42 0 -  
> 65 year 7 1 14.3  
Total 56 1 1.8 1,757 
 
NK: Not known. 
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Table 3.3: Influenza virus detections by country and age group for sentinel 
and non-sentinel specimens 
 
Country  Sentinel  Non-sentinel 
 Total number of 
specimens tested 
Number of 
specimens tested 
positive for RSV
Percentage 
positive (%)
Number of 
specimens tested 
positive for RSV 
England  
0-4 year 49 12 24.5 260 
5-14 year 63 33 52.4 81 
15-64 year 307 51 16.6 143 
> 65 year 45 2 4.4 45 
NK 11 3 27.3 12 
Total 475 101 21.3 541 
  
Scotland  
0-4 year 29 0 0 64 
5-14 year 67 16 23.9 53 
15-64 year 444 13 2.9 108 
> 65 year 58 2 3.4 31 
NK 1 
Total 598 31 5.2 257 
  
France  
0-4 year 426 82 19.2  
5-14 year 442 184 41.6  
15-64 year 557 109 19.6  
> 65 year 32 1 3.1  
Total 1,457 376 25.8 243 
  
Netherlands  
0-4 year 0 0  
5-14 year 7 3 42.9  
15-64 year 42 8 19.0  
> 65 year 7 4 57.1  
Total 56 15 26.8 239 
 
NK: Not known. 
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Discussion 
 
We have assessed whether EISS could be used to build a European RSV 
surveillance system. Surveillance systems must be timely in order to be 
effective. The EISS system has demonstrated timeliness in providing data on 
influenza and as this report shows in four countries, timely data on RSV. 
Sentinel data indicated that RSV contributed considerably to influenza-like 
illness, especially in young children. Since the infrastructure of EISS is well 
established24, we suggest the use of EISS as a model for setting up an RSV 
surveillance system in Europe.  
 
Healthcare based surveillance systems are dependent upon persons consulting 
doctors. For common respiratory infections, there are many more infected 
persons in the community who do not consult their doctor. Selection biases 
which start with the decision to consult are compounded at the point of 
consultation. In addition, sensible use of virological investigation does not 
necessarily mean that every suspect case is investigated. Certainly as far as 
patients in the community are concerned, routine virological investigation for 
a common condition which is usually minor is not economically justifiable. 
Furthermore, the patient’s willingness to be sampled will always be a major 
consideration.  
 
The EISS differentiates between sentinel and non-sentinel sources of data. 
Sentinel networks in Europe are chiefly based on general practices (and in 
some European countries also on paediatric primary care services) and these 
are essential to provide insight into what is happening in the community at 
large. However, the hospital admission is a useful proxy for severity of illness 
and it is desirable therefore to have access to additional hospital source data. 
This is particularly important when an illness is common in all age groups but 
hospital admission is much more likely in particular age groups. Accordingly we 
wish to encourage data collection from hospitals either on a routine basis from 
all hospitals or perhaps more thought might be given to the development of 
sentinel hospitals with a higher level of commitment to high quality data 
capture and more structured virological investigation.  
 
Our study has shown that the age distribution of RSV positive cases was similar 
in the four countries. For England relatively more RSV than influenza was 
reported but this was not so in the other three countries. A possible reason for 
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this could be the use of a more sensitive diagnostic test in England compared 
to the other countries. Within EISS the need for harmonization of laboratory 
methods is recognised and a Community Network of Reference Laboratories 
has been established in 2003. This Network encourages the harmonisation of 
laboratory methods for the detection of influenza in EISS and assesses the 
quality of laboratory testing for influenza and RSV.25 
 
To see whether the data for England were consistent with earlier findings, we 
compared our results to data published previously on RSV.10 More RSV than 
influenza virus was reported for one of the winter seasons (1997-98), this 
finding is similar to what we have reported for 2002-2003. It is important to 
note that differences between countries and seasons can simply be due to 
seasonal variation; lower proportions of RSV detections from patients with 
influenza-like illness have been observed for England as well.26 
 
The sentinel networks in all four countries used combined nose and/or throat 
swabs inserted in the same vial. These have proved reliable for influenza 
surveillance.27 However, the best site to collect material for viral detection 
may differ between influenza virus and RSV. Nasal swabs may be less specific 
than nasopharyngeal aspiration28, on the other hand swabs are probably less 
painful and easier to obtain in a general practice setting. Facilities for 
sampling patients in the hospital are generally better than those in the 
community since there may be increased opportunity for sample collection and 
less limitation on sample transportation with hospitals linked directly to 
microbiology laboratories. 
 
The diagnosis made, the selection of patients for swabbing, the quality of the 
swab taken, the transport procedures, the virological investigation methods 
and the experience of the laboratory concerned, all influence virus detection 
rates. The majority of sentinel respiratory specimens did not test positive for 
either influenza or RSV. This may be explained by other respiratory viruses 
that are known to cause symptoms similar to influenza and RSV infection29,30 
but few are regularly investigated. As an example, for Scotland, 83 (13.9%) 
sentinel swabs tested positive for picornavirus during the 2002-2003 winter 
season. Furthermore, positivity rates differed considerably between countries: 
e.g. in Scotland the percentage positive for RSV and influenza was only 8%. In 
the future, the EISS might implement more respiratory viruses for surveillance 
purposes simultaneously after introducing RSV. Nine countries in EISS already 
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tested sentinel specimens for more viruses than RSV and influenza in 2002, 
e.g. for human metapneumovirus, rhinovirus, coronavirus, adenovirus, C. 
pneumoniae or para-influenza virus. 
 
Discrepancies in positivity rates could reflect several factors mentioned above; 
but it is also possible that payment to general practitioners for taking swabs in 
Scotland leads to sampling bias. In addition, general practitioners in Scotland 
are requested to take samples from patients with acute respiratory infections 
in the absence of influenza. Relatively few respiratory specimens were 
collected by the Dutch sentinel network which can lead to underestimation of 
the incidence of RSV and influenza as judged from virological data. This seems 
in particular true for children and the elderly.  
 
The current methodological differences between countries and the constraints 
of the study (data for four countries and one season) impose limitations. Since 
we selected and analysed data for the four countries that tested sentinel 
specimens during the 2002-2003 season for RSV, we cannot state that all 
members of EISS are able to comply with routine RSV reporting. However, this 
study demonstrated that it is possible to report RSV in addition to influenza. 
We believe our results pave the way for the development of an RSV 
surveillance system running in parallel to influenza surveillance. 
 
 
Conclusions 
 
Our conclusions relate to recommendations for an RSV surveillance 
programme.  
1. Specimens collected as part of an influenza surveillance programme should 
also be tested for RSV. 
2. Both combined nose/throat swabs and nasal pharyngeal aspirates are 
acceptable for RSV diagnosis. 
3. The application of molecular techniques such as real time PCR in the 
diagnosis of respiratory disease has been demonstrated and we advocate 
this technique for RSV detection. 
4. We encourage further developments on the use of standardized methods 
and laboratory techniques. 
5. The development of a sentinel approach of representative hospitals should 
be considered. 
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6. We recommend the new networks joining EISS to integrate RSV 
surveillance alongside influenza. 
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Abstract 
 
Respiratory syncytial virus (RSV) surveillance is important to get insight into 
the burden of disease and epidemic pattern of RSV infection. This information 
is useful for healthcare resource allocation as well as the timing of preventive 
messages and palivizumab prophylaxis. For influenza surveillance the European 
Influenza Surveillance Scheme (EISS) was established in 1996, but no 
surveillance platform is available for RSV. To improve surveillance an RSV Task 
Group was established in 2003 and recommendations for RSV surveillance were 
developed. By 2008, progress was made for four out of six recommendations: 
the number of European countries testing specimens for RSV increased from six 
to fourteen; nose and/or throat swabs were generally used for detection of 
influenza and RSV; a total of 25 laboratories performed molecular testing for 
diagnosis and participated in a quality control assessment for RSV with an 
overall good performance; four of the ten countries that joined EISS in 2004 
started reporting RSV detections in addition to influenza in the period 2004-8. 
Limited progress was achieved for standardising methods and the development 
of a sentinel surveillance system of representative hospitals. Improving RSV 
surveillance is possible by further harmonising the data collection and 
increased reporting of RSV. 
 
 
Introduction 
 
Respiratory syncytial virus (RSV) is the most important viral agent causing 
severe respiratory disease in young children.1-3 RSV is also being recognised as 
a significant pathogen in adults2,4causing moderately severe respiratory disease 
especially in the elderly.5,6 Influenza is widely recognised as a major cause of 
morbidity and mortality in humans.7,8 Since RSV and influenza virus infections 
are associated with similar clinical symptoms9 and frequently co-circulate 
around the same time of the year, there is substantial potential for confusion 
regarding the cause of influenza-like illness.10 
 
Influenza and RSV account for similar numbers of deaths in children and their 
impact varies by winter and age group. RSV is associated with more deaths 
than influenza in children aged 1-12 months.11 Excess deaths due to RSV and 
influenza virus infection have also been reported for the elderly population.5,8  
When comparing cause-specific mortality due to influenza virus and RSV 
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infection in all ages, it has been estimated that most deaths were associated 
with influenza A(H3N2) viruses, followed by RSV, influenza B, and influenza 
A(H1N1).8 
 
While influenza is on the list of communicable diseases that must be covered 
by the European Community network for surveillance, RSV is not on this list.12 
Nonetheless, RSV causes considerable burden of disease and RSV surveillance is 
important for determining the burden of illness in all age groups and in 
defining seasonality and epidemic pattern. This facilitates the preparation of 
hospital settings to receive more children and to define the timing of the start 
of palivizumab prophylaxis.13 Palivizumab can be administered as passive 
immunoprophylaxis and is the only strategy that has been demonstrated to 
reduce RSV hospitalisations in high-risk children.14 For real-time influenza 
surveillance the European Influenza Surveillance Scheme (EISS), a collaborative 
multinational project, was established in 199615, but no such scheme was 
available for other respiratory viruses including RSV. Since RSV and influenza 
infections typically occur in the winter, EISS made it possible to report RSV 
detections into the EISS database, on a voluntary basis, from 1996 until 
September 2008.  
 
In 2003 an RSV Task Group was established within EISS to explore the 
possibility to design a comprehensive RSV surveillance scheme within the EISS 
framework. This Task Group was composed of four epidemiologists and two 
virologists. Three meetings were organised between July 2003 and January 
2006 and updates on the activities were presented to the EISS group during the 
EISS Annual Meetings. A retrospective analysis was carried out. Additionally, 
RSV surveillance recommendations were published in 200616, and are presented 
below: 
1) Specimens collected as part of an influenza surveillance programme should 
also be tested for RSV. 
2) Both combined nose/throat swabs and nasal pharyngeal aspirates are 
acceptable for RSV diagnosis. 
3) The application of molecular techniques such as real time PCR in the 
diagnosis of respiratory disease has been demonstrated and we advocate 
this technique for RSV detection. 
4) Further developments are encouraged on the use of standardised methods 
and laboratory techniques. 
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5) The development of a sentinel approach of representative hospitals should 
be considered. 
6) New countries joining EISS are encouraged to integrate RSV surveillance 
alongside influenza surveillance. 
 
Our objective was to assess whether the RSV reporting within EISS in the 
period 2004-2008 complied with these surveillance recommendations, and to 
describe the detection and reporting of seasonal influenza and RSV infections 
in six selected countries in Europe. 
 
 
Methods 
 
Data collection in EISS 
EISS was based on an integrated clinical and virological surveillance model. 
Sentinel primary care physicians reported weekly the number of new cases of 
influenza-like illness and/or acute respiratory infections and obtained 
respiratory specimens from a sample of patients for laboratory testing. The 
specimens were tested for influenza and in several countries for RSV as well. 
Weekly consultation rates and laboratory test results were entered by the 
national surveillance networks into the EISS database via an internet-based 
system.17 Non-sentinel, mainly hospital-based data for influenza and RSV were 
also collected, but will not be presented in this paper.  
 
Since September 2008, European influenza surveillance has been carried out by 
the European Centre for Disease Prevention and Control (ECDC) and involves 
all 27 European Union Member states and Norway. Three other countries 
Serbia, Switzerland and Ukraine are reporting data to WHO Europe.  
 
This paper presents a descriptive study. Surveillance data for seven winter 
seasons (2001-2 to 2007-8; week 40-20) in the EISS database were screened for 
RSV detections by country. The database containing virological detections of 
RSV and influenza was downloaded by September 2008. An RSV reporting 
country was defined as a country that reported at least 10 sentinel specimens 
positive for RSV from 2001-2008. With this method the progress for 
recommendation 1 and 6 could be assessed. For the other recommendations 
the progress was summarised by collecting relevant data from inventories and 
a quality control assessment. 
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RSV detections: six countries 
Country selection 
Data from the Czech Republic, France, Germany, Netherlands, Slovenia and 
the United Kingdom (UK) (represented by England and Scotland) were assessed 
to describe the RSV surveillance in these countries. All had reported data for 
at least five winter seasons. Sentinel primary care physicians included general 
practitioners (GPs) in the United Kingdom and the Netherlands, and GPs and 
paediatricians in the Czech Republic, France, and Germany, and GPs, 
paediatricians and specialists in Slovenia. The sentinel doctors represented 1-
5% of all physicians working in the country. 
 
Case definition 
Data on new cases were based on reporting of consultations for influenza-like 
illness (ILI) in the Netherlands, Slovenia and United Kingdom. Consultations for 
acute respiratory infections (ARI) were collected in France and Germany. From 
2001-2 to 2004-5 the Czech Republic reported the number of new cases of ARI, 
and from 2005-6 onwards they reported cases of ILI in addition to ARI.18 Case 
definitions for ARI and ILI differed slightly between countries.19 The type of 
specimen that was collected (nose and/or throat swab) as well as transport 
conditions were similar.20 Samples were generally collected within five days 
after onset of symptoms and systematically tested for both influenza virus and 
RSV in all countries. In Germany, only specimens of children aged 0-3 years 
were tested for RSV. Cases were defined positive for RSV or influenza when at 
least one laboratory test yielded a positive result. Between-country 
comparisons will not be made due to methodological differences.  
 
 
Results 
 
Recommendation 1 
Specimens collected as part of an influenza surveillance programme should 
also be tested for RSV. 
 
Seventeen countries had reported RSV detections in the period 2001-2008: 
Austria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Italy, Luxembourg, Netherlands, Poland, Romania, Slovenia, Slovakia, 
Switzerland, UK- England and Scotland. Since England and Scotland have their 
own sentinel surveillance systems, these are presented separately in this 
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paper. The number of countries reporting influenza data increased from 18 in 
2001-2 to 31 in the winter of 2007-8 (Table 4.1). 
 
In 2001-2 only six countries reported RSV detections in addition to influenza, 
but their number gradually increased, particularly around 2003-4, among both 
countries that had participated since 2001 and new member states (see also 
results for recommendation 6). From 2005-6 no further increase in the number 
of countries reporting RSV was observed (Table 4.1). 
 
 
Table 4.1: Reporting of RSV and influenza data to EISS in the period 2001-
2008 
 
Season  Countries 
reporting RSV* 
Countries reporting 
influenza 
Number RSV 
detections 
Number influenza 
detections 
2001-2002 6 18 203 2276 
2002-2003 8 19 335 3787 
2003-2004 12 22 143 2732 
2004-2005  12 23 557 5483 
2005-2006 14 28 803 3171 
2006-2007 14 30 888 5077 
2007-2008 13 31 929 5076 
 
* 2001-2002: CZ, FR, DE, SI, CH, UK-E, UK-S. 
2002-2003: CZ, FR, DE, NL, SK, SI, CH, UK-E, UK-S. 
2003-2004: CZ, FR, DE, NL, SK, SI, CH, UK-E, UK-S. 
2004-2005: AT, CZ, DK, FR, DE, IT, LU, PL, RO, SI, CH, UK-E, UK-S. 
2005-2006: AT, CZ, DK, EE, FI, FR, DE, IT, LU, NL, PL, RO, SI, UK-E, UK-S. 
2006-2007: AT, CZ, DK, EE, FI, FR, DE, IT, LU, NL, PL, RO, SI, UK-E, UK-S. 
2007-2008: AT, HR, CZ, DM, EE, FI, FR, DE, LU, NL, PL, SI, UK-E, UK-S. 
 
Abbreviations: Austria (AT), Croatia (HR), Czech Republic (CZ), Denmark (DK), Estonia (EE), 
Finland (FI), France (FR), Germany DE), Italy (IT), Luxembourg (LU), 
Netherlands (NL), Poland (PL), Romania (RO), Slovenia (SI), Slovakia (SK), 
Switzerland (CH), UK-England (UK-E), UK-Scotland (UK-S). 
 
 
Recommendation 2 
Both combined nose/throat swabs and nasal pharyngeal aspirates are 
acceptable for RSV diagnosis. 
 
Different types of specimens are used for detection of influenza and RSV.21 
Generally the nasopharyngeal aspirates have a high sensitivity, and are often 
used in a hospital setting. Easier to use and less painful are 
nasal/nasopharyngeal swabs.22 An inventory carried out in 2002 indicated that 
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in sentinel surveillance systems in Europe nose and/or throat swabs were 
taken.20 Twelve out of 20 national networks collected combined nose/throat 
swabs. The remaining networks collected either nasopharyngeal, nasal, or 
throat swabs. In addition, three networks took blood samples and one network 
obtained nasal aspirates.20 Since all countries had already used the 
recommended type of respiratory sample and fulfilled the recommendation, no 
progress was assessed after 2002. 
 
Recommendation 3 
The application of molecular techniques such as real time polymerase chain 
reaction (PCR) in the diagnosis of respiratory disease has been demonstrated 
and this technique is advocated for RSV detection. 
 
In 2006, laboratories were invited to participate in a quality control study for 
molecular methods. Of the 33 laboratories participating in EISS, 25 performed 
this technique with an overall performance of 88% correct results.23 The 
majority (22 out of 25) of laboratories used an in-house molecular assay. In 
particular, real time PCR and nested PCR assays provided the highest 
performance scores (93% correct score; range 70-100) and were used in 19 
laboratories. Three laboratories used commercial assays and the percentage of 
correct results ranged from 50% to 80%.23 
 
Recommendation 4 
Further developments in the use of standardised methods and laboratory 
techniques are encouraged. 
 
Limited progress was made in standardising methods. Only for influenza, not 
RSV, laboratory protocols were shared and standardised reagents were made 
available via the EISS website. However, with the application of molecular 
methods, as indicated in recommendation 3, and quality control assessment of 
this method, the quality of laboratory testing of RSV is ascertained. 
 
Recommendation 5 
The development of a sentinel system of representative hospitals should be 
considered. 
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No efforts were made to develop a European sentinel surveillance system 
consisting of representative hospitals, though national initiatives may have 
been undertaken. For example, a laboratory-based surveillance for RSV 
involving different hospital laboratories in Slovenia was implemented in 2006.24 
 
Recommendation 6 
We recommend the new networks joining EISS to integrate RSV surveillance 
alongside influenza. 
 
Ten new countries became members of EISS between 2004 and 2008: Austria, 
Bulgaria, Croatia, Estonia, Finland, Cyprus, Greece, Hungary, Ukraine and 
Serbia.25 Of these, four countries followed the recommendation and started 
reporting RSV data (Table 4.1). 
 
RSV detections: six countries 
To illustrate the data that were collected by EISS, we present the results of 
RSV detections for six countries. All countries reported at least five seasons of 
data, which provided insight in the occurrence of RSV in these countries. RSV 
and influenza detections are presented in Table 4.2. The percentage of RSV-
positive specimens largely differed by season, e.g. from 3% to 19% in the Czech 
Republic (Table 4.2). For all seasons and countries together the percentage of 
RSV-positive specimens varied from 4% in Germany and the Netherlands to 16-
18% in the United Kingdom. RSV activity usually started a few weeks before the 
onset of influenza activity (data not shown). The data collected are useful to 
describe the seasonality of RSV and show that RSV is detected in patients with 
ILI and/or ARI. 
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Table 4.2: Number of sentinel influenza and RSV detections by country in the 
period 2001-2008. The relative percentage of RSV cases is 
presented by the total number of tested samples 
 
Country RSV detections 
per season
Mean (range)
Influenza 
detections per 
season
Mean (range)
Total RSV and 
influenza detections
Mean (range)
% RSV 
 
(range) 
Czech Republic 18 (5-30) 206 (83-311) 223 (102-327) 8 (3-19) 
France 145 (47-227) 1053 (824-1374) 1198 (947-1601) 12 (4-18) 
Germany 43 (12-138) 1129 (553-2145) 1172 (568-2172) 4 (1-10) 
Netherlands* 12 (1-19) 121 (15-142) 133 (16-153) 4 (0-16) 
Slovenia 6 (1-12) 101 (69-132) 106 (77-135) 5 (1-12) 
UK-England 44 (14-125) 231 (82-432) 275 (107-477) 16 (8-56) 
UK-Scotland 23 (14-35) 101 (31-193) 123 (50-220) 18 (11-38) 
 
* No RSV detections were reported for the Netherlands in the winters of 2001-2002 and 2004-
2005.  
 
 
Discussion and conclusion 
 
Progress in RSV surveillance was made in the period 2001-2008, with the most 
obvious increase in the number of reporting countries during the time the RSV 
Task Group was active, between 2003-2006. Progress was made particularly in 
terms of the number of countries testing specimens for RSV and the use of 
molecular techniques. The results for the six countries that had reported at 
least five years of data showed that RSV surveillance and reporting is feasible 
in Europe. The overall percentage of RSV-positive specimens for the Czech 
Republic, France, Germany, Netherlands, Slovenia and the UK amounted to 4-
18% indicating that a substantial number of patients who consulted their 
sentinel physician with influenza-like illness or acute respiratory infection 
actually had an RSV infection. The EISS surveillance is real time and therefore 
can be relevant for timing of the influenza and RSV peak and providing insight 
into the morbidity and seasonality of these respiratory illnesses. 
 
Limited progress was made for recommendation 4 on the use of standardised 
laboratory methods. With the use of mainly in-house developed methods that 
perform well23, the standardising of methods was not further explored. The 
rationale was that standardising methods is important and is encouraged by 
sharing protocols, but more important is the ability of the laboratory test to 
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correctly identify RSV. Furthermore, limited progress was made for 
recommendation 5 on the development of a sentinel approach of hospitals. 
This recommendation was ranked as a lower priority because non-sentinel data 
from hospitals are currently being collected. The non-sentinel data could be 
used for the future establishment of a sentinel laboratory monitoring system 
and would then need to be assessed for representativeness and quality of data 
collection. 
 
In this paper we presented data on sentinel RSV and influenza detections. 
Relatively low numbers of positive RSV tests were reported and this is 
therefore a limitation. In addition to sentinel data, RSV reports from non-
sentinel sources, mainly derived from hospitalised infants are also available 
and these can provide insight into the epidemic peak of RSV during wintertime. 
We think that both sources of data are important and complement each other. 
Sentinel data highlights the occurrence of RSV in the community, where it is an 
important confounder in influenza surveillance. And hospital-based data 
present the circulation of RSV in more severe cases and high-risk groups. 
 
The limitations of the sentinel influenza surveillance carried out by EISS are 
related to differences in case definitions19, sampling guidelines and laboratory 
techniques among the different countries.20 Some difficulty in obtaining swabs 
from all age groups has been reported, especially for young children in the 
Netherlands and the elderly in the Netherlands and France.16 Another 
limitation is that we could not further investigate other possible causes of 
respiratory infections such as rhinovirus, adenovirus and coronavirus26,27 and 
human metapneumovirus.28 Country resources however may limit the extension 
of testing for other viruses in addition to influenza and RSV. Furthermore, no 
comparison regarding the occurrence of RSV and influenza between the 
different countries could be made because of differences in data collection 
procedures and laboratory methods. Additionally, differences in healthcare 
seeking behaviour may influence the findings between countries. 
 
Currently diagnostic specimens are collected from patients presenting with ILI 
or ARI. Although ILI and/or ARI case definitions have been used for the 
detection of influenza for many years, this may not be the optimal clinical 
indicator for RSV. To investigate the clinical impact and determine the burden 
of illness of RSV one should extend the diagnostic categories to include acute 
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bronchitis and otitis media.29 This may become feasible with the movement 
towards sentinel networks based on electronic data. 
We presented the progress in RSV surveillance based on an influenza 
surveillance network and data collected for six countries. This illustrated the 
feasibility of reporting RSV data and showed that a proportion of about 4-18% 
of the patients were infected with RSV. Sentinel monitoring of RSV and 
influenza virus is important and may even be extended to other respiratory 
viruses as the development of multiplex PCR30 facilitates the detection of 
other causative agents of respiratory illness. All countries are encouraged to 
test their specimens for RSV and improvements can be made as less than half 
of the countries participating in EISS had reported these data. Furthermore, 
swabbing procedures should be further harmonised and regular quality control 
of laboratory methods should be performed. When these criteria are met, 
surveillance of RSV and influenza virus will contribute to a better insight into 
the burden of respiratory diseases and may be used by healthcare 
organisations to decide on the timing of palivizumab prophylaxis for RSV in 
Europe. Overall, this paper illustrated that an existing influenza surveillance 
system can be relatively easily broadened to include the surveillance of RSV 
and may be extended to other viruses in the future. 
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Abstract 
 
Respiratory syncytial virus (RSV) is the most important viral agent causing 
severe respiratory disease in infants and children. In temperate climates, RSV 
activity typically peaks during winter. We have described the seasonal 
variation in RSV activity and investigated which meteorological variables are 
related to RSV outbreaks for different time lags. Eleven laboratories in the 
Netherlands collected data on RSV during the period 1998-2005. Meteorological 
data were obtained from the Royal Netherlands Meteorological Institute. 
General linear methods were used to determine the relative contribution of 
meteorological conditions to reported RSV cases in the winter period. Time 
lags up to 4 weeks were included to assess a possible delayed weather effect in 
relation to RSV activity. Onset of RSV activity occurred around week 44 and 
activity peaked around week 52. Timing of peak activity was very consistent 
over the study period. Relative humidity was positively associated with RSV 
activity for all time lags, indicating more RSV when relative humidity 
increased. Minimum temperature was negatively associated with RSV activity 
and cloud cover was positively related with RSV activity. Interaction (p<0.06) 
between minimum temperature and relative humidity was observed for a lag 
of 0, 1 and 2 weeks, indicating that the combination of low temperature and 
high humidity contributes more to RSV activity than temperature and humidity 
alone. Relative humidity, minimum temperature, and cloud cover are 
important predictors of RSV activity in the Netherlands, with the effect of 
relative humidity being most consistent. 
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Introduction 
 
Respiratory syncytial virus (RSV) is the most important viral agent causing 
severe respiratory disease in infants and children worldwide.1 Most children 
have been infected at least once by the age of two and re-infections occur 
throughout life.2 The symptoms of an RSV infection range from a very mild 
illness to serious lower respiratory tract infections including bronchiolitis and 
pneumonia. Although infrequently recognized, RSV is common in adults and 
can be the cause of severe illness especially in the elderly.3 The average 
annual rate of RSV-associated hospitalization has been reported to be 3 (range 
2-6) per 1000 children and 17 (range 12-34) per 1000 children under the age of 
six months.4 Mortality rates in children are low, RSV attributed deaths have 
been estimated at 8.4 per 100 000 population. More than half of the attributed 
deaths in children aged 1 month to 14 years occurred in babies aged 1-12 
months.5 
 
In temperate climates, RSV activity typically peaks during the winter. 
Epidemics are related to geographic and climatic factors, but it is not clear 
whether this is related to the spread of virus, indoor crowding or 
immunological susceptibility of the population.6 For the influenza virus, 
another respiratory virus that circulates during wintertime, transmission is 
dependent on relative humidity and temperature.7 This evidence supports the 
role of weather conditions in the dynamics of influenza and may also be 
applicable for RSV transmission. However the mode of transmission differs 
slightly between the two viruses. RSV is transmitted by large-particle aerosols 
and by direct contact with RSV in solutions of human secretions8, while 
influenza is spread via small droplets as people sneeze, cough or talk. 
 
Meteorological conditions such as temperature, relative humidity and UV-B 
radiation have recently been described in relation to RSV epidemics.6,9,10 A 
study performed in Spain indicated that low levels of temperature and low 
absolute humidity were positively associated with the number of RSV cases and 
low absolute humidity was independently related to RSV infection.9 Worldwide, 
RSV peaks at two temperature intervals: between 2-6°C in temperate regions 
and 24-30°C in tropical regions. RSV activity was greatest at 45-65% relative 
humidity and UV-B radiance was inversely related to the number of RSV 
cases.10 So far, mainly crude associations between RSV activity and weather 
have been assessed and correlations between the meteorological variables 
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have not always been taken into account. In addition, weather models have 
usually not included a time delay effect on RSV, while one would expect some 
delay between weather changes and RSV activity. 
 
RSV epidemics occur yearly but may alternate in occurrence between mid-
winter and early spring.11,12 A biannual rhythm with an early RSV season 
followed by a late season has been described for Finland, Germany and 
Croatia.12-14 Year-to-year national and regional variability in the RSV season 
onset and offset occurs in the United States.15 Appropriately timed diagnostic 
testing can provide data that indicate when the RSV season begins nationally 
and regionally, information that is critical in determining when to begin RSV 
prophylaxis for infants at high risk for infection. The monoclonal antibody 
palivizumab offers protection against complications, and the first of the five 
monthly doses should be administered before onset of community RSV activity. 
In this paper, we investigate which meteorological factors can predict RSV 
outbreaks and describe the year to year variation of RSV activity in the 
Netherlands. To adjust for the incubation time and possible delayed weather 
effects, four time lags were included in the model to assess the relation of 
weather variables with RSV activity. 
 
 
Methods 
 
Design 
The role of meteorological variables on RSV was assessed during RSV active 
periods in eight consecutive years (1998-2005). Data about RSV activity were 
derived from a central computer-based data system, the Infectious diseases 
Surveillance Information System (ISIS), based at the National Institute for 
Public Health and the Environment. Meteorological data were available on a 
daily basis for ten variables and collected by the Royal Netherlands 
Meteorological Institute (KNMI). We used the number of RSV confirmed cases 
per week as the outcome variable and investigated whether there was an 
association between weather variables and RSV in the Netherlands. 
 
Selection of RSV active periods 
All analyses were restricted to RSV active periods, starting at week 40 and 
ending in week 20 of the following year. The season onset and offset criteria 
for RSV were based on those of the National Respiratory and Enteric Virus 
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Surveillance System.16 We defined the week of onset as the first of two 
consecutive weeks in which at least 10% of the tested samples tested positive 
for RSV and a minimum of 10 samples were tested in that week. Offset was 
defined as the last of two consecutive weeks with at least 10% of the samples 
tested positive for RSV and a minimum of 10 samples tested in that week. All 
seasons included a week 53 that usually comprised one or two days. For 
defining the onset and offset, we have compared the threshold of 10 tests per 
week to a threshold of 20 tests per week. The threshold of 20 samples showed 
little difference for the onset, but large difference in defining the offset. We 
defined the threshold at 10 tests per week, which was most sensitive in 
determining the onset and offset of the RSV active period. The duration was 
defined as the number of weeks from onset to offset. 
 
RSV data  
Data were derived from ISIS. This system automatically collects data on a daily 
basis on RSV from regional laboratories and/or hospitals in the Netherlands and 
these were mainly concentrated in the middle and southern regions of the 
Netherlands (Figure 5.1). Data from eleven laboratories were included and 
contained information on the age of the patient, gender, four digit postal 
code, type of material sampled and the laboratory method. Both positive and 
negative test results were recorded. All test results were anonymously and 
uniquely coded for each patient. 
 
To estimate the population coverage of the laboratories, we looked at the 
laboratories that reported to ISIS in 2000 (n=9) and compared this to the total 
number of laboratories (n=58) in the Netherlands as a whole.17 The coverage of 
the ISIS laboratories was estimated at 2.4 million, which covers around 16% of 
the Dutch population. It was assumed that all patients with severe RSV 
infection in the region would be picked up by the regional laboratory. 
Participating laboratories generally used one or two diagnostic methods: (in) 
direct immuno-fluorescence (n=6), culture (n=5), antigen detection (n=3), or 
enzyme-linked immunosorbent assay (ELISA) (n=2). In the Netherlands, an 
attempt is usually made to come to an RSV diagnosis in hospitalized 
bronchiolitic infants. Diagnostic tests are rarely performed in non-hospitalized 
children with respiratory symptoms. 
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Figure 5.1: Geographical distribution of the laboratories that reported RSV 
data (a), and the number of RSV cases in the different postal 
codes reported by the laboratories in the period 1998-2005 (b) 
 
a. b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meteorological data 
The Royal Netherlands Meteorological Institute (KNMI) collects daily 
meteorological data in the Netherlands. Data was obtained from a centrally 
located weather station (De Bilt) and included: prevailing wind direction in 
degrees (360=North, 180=South, 270=West, 0=calm/variable), daily mean wind 
speed in 0.1 m/s, daily mean temperature in 0.1 degrees Celsius, minimum 
temperature in 0.1 degrees Celsius, maximum temperature in 0.1 degrees 
Celsius, sunshine duration in 0.1 hour, percentage of maximum possible 
sunshine duration, daily precipitation amount in 0.1 mm (-1 for < 0.05 mm), 
daily mean surface air pressure in 0.1 hPa, cloud cover in octants (0 = no 
clouds – 9 = sky invisible), and daily mean relative atmospheric humidity in 
percentage. 
 
The absolute humidity is directly related to the temperature and relative 
humidity, and was calculated by multiplying relative humidity with water 
vapor, as has been previously described in Lapena et al.9 For the prevailing 
wind direction, we categorized the four wind directions and calculated the 
most frequently observed wind direction in the form of the modus per week. 
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The weekly sum of precipitation data was used, and for all other weather 
variables the data were aggregated to the week average value. 
 
Data analysis 
The outcome variable was the number of positive cases of RSV per week during 
RSV active periods. Multiple linear regression analysis was performed on all 
weekly aggregated weather variables and the number of cases of RSV for all 
years. Variables were checked for correlation. Poisson and negative binomial 
regression analyses were performed in addition to the linear regression 
analysis. Week 53 consisted of one or two days and the RSV cases for this week 
were extrapolated to a whole week for the analysis. Weather data for week 53 
were not extrapolated, because all weather variables, except precipitation, 
were aggregated to the week average value.  
 
Because the incubation time of RSV infection is 2-7 days and there might be a 
delay in the weather effect in relation to RSV infection, different time lags (no 
lag, lag of one week, lag of two weeks, lag of three weeks, lag of four weeks) 
were included in the regression analyses. The descriptive and linear regression 
analyses were performed using SPSS 14. STATA 9 was used for the Poisson and 
negative binomial regression analysis and the robust option was used to adjust 
for heterogeneity in the model.18 Significance was concluded when p<0.05. 
 
The interaction between relative humidity and minimum temperature was 
calculated by multiplying the two variables. The minimum temperature was 
multiplied by -1 before calculating the interaction because this variable was 
negatively associated with RSV activity and opposite to the association of RSV 
with relative humidity. Significance of interaction was concluded when p<0.1. 
 
 
Results 
 
Demographics 
Data from eleven laboratories for the period 1998 to 2005 were included in the 
analyses. A total of 10672 tests were performed during the RSV active periods. 
Baseline characteristics of the participating laboratories can be found in Table 
5.1. Most cases were infants aged below 6 months and more boys than girls 
tested positive for RSV which corresponds with previous studies.19,20  
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Table 5.1: Baseline laboratory/hospital and patient characteristics in the 
period 1998-2005 
 
Laboratory/hospital Period 
reporting in 
winter 
seasons 
Number 
of tests 
Number of 
positive 
RSV tests 
(%) 
Median 
age in 
months 
(range) 
Gender  
(% male) 
1) Bosch Medisch Centrum, Den 
Bosch 
98/99-04/05 2235 1090 (49%) 4 (0-149) 57 
2) Canisius Wilhelmina Hospital, 
Nijmegen  
99/00-02/03 853 274 (32%) 4 (0-44) 54 
3) Laboratory for Infectious 
Diseases, Groningen 
02/03-05/06 2669 751 (28%) 4 (0-975) 61 
4) Laboratorium Microbiologie 
Twente Achterhoek, Enschede 
00/01,02/03
-05/06 
669 233 (35%) 5 (0-86) 64 
5) Ruwaard van Putten Hospital, 
Spijkenisse 
01/02-05/06 341 123 (36%) 4 (0-39) 57 
6) St. Antonius Hospital, 
Nieuwegein 
98/99-05/06 1001 393 (39%) 4 (0-965) 59 
7) St. Elisabeth Hospital, Tilburg 02/03-05/06 720 253 (35%) 3 (0-43) 55 
8) St. Jans Gasthuis, Weert 98/99-05/06 415 160 (39%) 4 (0-40) 60 
9) St. Laurentius Hospital, 
Roermond 
98/99-05/06 890 416 (47%) 5 (0-85) 55 
10) Streeklaboratorium Zeeland, 
Terneuzen 
98/99-05/06 686 208 (30%) 5 (0-39) 57 
11) Streeklaboratorium Zeeland, 
Goes 
99/00-05/06 193 101 (52%) 3 (0-52) 65 
      
Total  10672  4002 (38%)    
 
 
Seasonal trends 
The number of participating laboratories increased from five in 1998 to eleven 
in 2002-2003 (Table 5.2). In 2005, the season only contained data up to week 
52, and therefore fewer cases were reported for this season. The onset of RSV 
activity occurred around week 44, peaked around week 52, and was quite 
consistent for the study period. The duration and offset differed somewhat by 
season. Relative humidity and cloud cover were similar for the different 
seasons around both the onset and the peak of RSV activity. Some differences 
in the minimum temperature are observed for the different winters with a 
generally lower temperature around the peak (Table 5.2). 
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Association with meteorological factors 
The consistent onset would suggest some factor that triggers the RSV activity. 
This factor may be related to the weather. We assessed whether the weather 
variables were correlated with the weekly number of RSV cases. The first step 
was to assess the correlation between weather variables. A strong correlation 
(r > 0.8) was observed for 1) minimum temperature and absolute humidity, 2) 
relative humidity and sunshine duration, and 3) cloud cover and sunshine 
duration. Additionally, correlation was observed for the three temperature 
variables: minimum, mean and maximum temperature. We therefore excluded 
the following variables from the analyses: absolute humidity, sunshine 
duration, mean temperature and maximum temperature. The minimum 
temperature and relative humidity have been suggested as predictors of RSV 
activity in earlier studies9,10 and were included in the analysis, as well as the 
other weather variables that did not present a high correlation with other 
weather variables. 
 
The wind speed, modal prevailing wind direction, minimum temperature, 
precipitation, air pressure, cloud cover and relative humidity were assessed on 
the relation with weekly number of RSV cases (Pearson correlation). The 
relative humidity (r = 0.340), minimum temperature (r = -0.338), and cloud 
cover (r = 0.221) were significantly correlated with the weekly number of RSV 
cases and this finding was observed for all time lags, although the r-value 
decreased with increasing time lag for relative humidity and cloud cover. 
 
We also emphasized to illustrate the relation of weather variables with RSV 
activity. The weekly number of RSV positive patients is presented for the 
weeks 40 to 20 during 1998-2005, as well as the weather variables minimum 
temperature, relative humidity and cloud cover (Figure 5.2). For the three 
weather variables the weekly values were quite variable. The temperature at 
the beginning and end of the season was higher compared to the middle of the 
season when RSV activity was at its peak. A general drop in temperature 
around the RSV peak was most obvious for the period 2000-2003. Relative 
humidity was generally higher around the RSV peak, while at the end of the 
season a sudden drop in relative humidity can be observed. The figure 
presenting cloud cover and RSV also shows that RSV peaked around the time 
the highest cloud cover was reported. Although the weekly variation of the 
variables makes it difficult to track any subtle effects, this figure allow us to 
visualize a relation of meteorological factors with RSV. 
81 
Chapter 5 
Figure 5.2: RSV detections and minimum temperature (°C), relative humidity 
(%) and cloud cover (octant*10) in the winter periods 1998-2005 in 
the Netherlands. The weekly mean values of the weather variables 
are presented on the y-axis 
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Multiple linear regression analysis was initially performed for each of the years 
separately (data not shown). At least one of the meteorological factors, 
minimum temperature, relative humidity and cloud cover, was significantly 
associated with RSV activity in seven out of eight winters seasons: 1998-99, 
2000-01 to 2004-05. Relative humidity was a significant factor in the winter of 
2000-01, 2001-02, 2003-04, 2004-05 for multiple time lags. Temperature was 
significantly associated with RSV in four winters, varying from lag = 0 to lag = 
2. Cloud cover was significantly associated with RSV in three winters for lag = 0 
and/or lag =1. 
 
For all seasons together, we performed multiple linear regression analysis and 
evaluated the model with the number of RSV cases as dependent variable, and 
the relative humidity, minimum temperature and cloud cover as independent 
variables. This model explained about 21% of the variance in RSV cases (R2 = 
0.209; see Table 5.3). When looking at the same model for different time lags, 
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which ranged from one to four weeks, the effect of the weather variables 
decreased: R2 from 0.209 to 0.165. 
The relation of temperature with RSV was negative, indicating more RSV 
activity when the temperature decreased. A positive relation was observed for 
relative humidity and to some extent for cloud cover, indicating more RSV 
when the relative humidity or cloud cover increased. The minimum 
temperature contributed to the RSV cases for most time lags (0-3 weeks). The 
relative humidity still played an important role at the time lag of 4 weeks 
(Table 5.3). Cloud cover was borderline significant (p=0.051) in relation with 
RSV in the first time lag. In order to investigate whether the effect of one 
meteorological variable on RSV activity depends on the level of a second 
weather variable we calculated the interaction effect of minimum 
temperature and relative humidity on RSV activity and included this in the 
regression model (Table 5.4). There was an interaction effect at lag = 0 
(p=0.018), lag = 1 (p=0.053) and lag = 2 (p=0.059) and the role of temperature 
was reduced and borderline significant at lag =1. 
 
 
Table 5.3: Multiple linear regression analysis with the number of RSV cases as 
the dependent variable, and minimum temperature, relative 
humidity and cloud cover as independent variables for different 
time lags expressed in standardized beta coefficients and 
explained variance (R2) 
 
Weekly number 
RSV cases 
Weekly mean min. 
temperature 
Weekly mean 
relative humidity 
Weekly mean  
cloud cover R
2 
No lag -0.321** 0.203** 0.141a 0.209 
Lag 1 week -0.243** 0.282**  0.123 0.201 
Lag 2 weeks -0.226** 0.358**  0.046 0.206 
Lag 3 weeks -0.153* 0.404**  -0.014 0.185 
Lag 4 weeks -0.043 0.433**  -0.071 0.165 
 
* p< 0.05   ** p< 0.01. 
a The p-value is borderline significant: p = 0.051. 
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Table 5.4: Multiple linear regression analysis with the number of RSV cases as 
the dependent variable, interaction between minimum 
temperature and relative humidity, minimum temperature, 
relative humidity and cloud cover as independent variables for 
different time lags expressed in standardized beta coefficients 
and explained variance (R2) 
 
Weekly 
number RSV 
cases 
Interaction minimum 
temp and relative 
humiditya 
Weekly mean 
min. 
temperature 
Weekly mean 
relative 
humidity 
Weekly 
mean  
cloud cover 
R2 
No lag  1.566* 1.256 b 0.339** 0.142* 0.227 
Lag 1 week 1.359b*   1.120 0.389**  0.124 0.213 
Lag 2 weeks  1.581c*   1.354 0.464**  0.043 0.219 
Lag 3 weeks  1.339  1.183 0.487**  -0.014 0.193 
Lag 4 weeks  1.044  0.996 0.491**  -0.071 0.166 
 
Note: Interaction between minimum temperature and relative humidity calculated by 
(minimum temperature (*-1)) * (relative humidity). 
 
For the three weather variables:  
* p< 0.05   
** p< 0.01 
a  For the interaction term significance was concluded when p<0.1. 
b  p = 0.053. 
c  p = 0.059. 
 
 
In addition to multiple linear regression analysis, Poisson regression was 
carried out as count data are highly non-normally distributed and are better 
estimated by Poisson regression. The results of the Poisson regression analysis 
were identical for the minimum temperature and relative humidity as 
performed by the linear analysis (data not shown). In the Poisson regression 
cloud cover was a significant factor at no lag (p<0.01) and a lag of one week 
(p<0.05) where the linear regression found a borderline significant effect at no 
lag (p = 0.051). Poisson regression assumes that the mean and the variance are 
the same; our dataset did not fit this assumption. Therefore we also performed 
negative binomial regression, which is better fit for over-dispersed data. For 
all three meteorological factors the previous Poisson analysis was confirmed. 
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Discussion 
 
Our data showed that relative humidity, minimum temperature and cloud 
cover were important predictors of RSV activity for different time lags in the 
Netherlands. The effect of the time lag is relevant and the three 
meteorological factors contributed most to the model at lags 0 to 2 weeks, 
indicated by the R2 explaining the variance in RSV cases for about 22%. The 
effect of meteorological factors was not statistically significant for all 
individual winter seasons, but this was expected due to the loss of power in 
particular the 1998-99 and 1999-00 winters when a low number of samples 
were tested for RSV in these periods.  
 
Most obvious was the positive relation of RSV with the relative humidity that 
showed significant association for all time lags, also after adding an interaction 
term into the regression model. Minimum temperature was inversely related to 
RSV and this parameter contributed to RSV activity in three out of the four 
time lags. After addition of the interaction parameter into the model the 
effect of minimum temperature decreased. The interaction found between 
relative humidity and minimum temperature highlighted that the combination 
of the two parameters have a stronger impact on RSV activity than each of the 
parameters alone and better fitted the model as R2 was higher.  
 
The consistent peak week of RSV activity observed for the Netherlands has also 
been reported for the United Kingdom, but differs from reports made for 
Croatia and Finland. In Croatia and Finland RSV outbreaks occur in every 
second year causing a mild spring peak, followed by a larger outbreak in the 
winter during the same year. For Croatia the large RSV outbreak was inversely 
related to the temperature and directly to humidity13. But the subsequent 
winter is rather silent, and the role of meteorological factors did not explain 
the timing of RSV outbreak in Croatia. Differences in outbreaks between 
countries may be related to the climate and population density. The 
Netherlands has a temperate, marine climate, similar to the United Kingdom. 
Croatia has a Mediterranean and continental climate, while Finland has a cold 
temperate climate. Population density in the Netherlands is 395 
inhabitants/km2, while in Finland it is 16 inhabitants/km2 and in Croatia 81 
inhabitants/km2.21 The silent winter might be explained by the effect of the 
low population and thereby a low number of susceptible children, which lowers 
spread of RSV. 
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The relation between RSV activity and low minimum temperature may indicate 
that a low temperature enhances virus transmission. It has been described in 
earlier studies that transmission of RSV is inversely related to temperature in 
cooler climates and this may be a result of increased stability of the virus in 
the secretions in the colder environment.10 A limited amount of literature is 
available on RSV transmission and the role of temperature and humidity, but 
has been investigated for influenza, also a typical winter disease. Lowen et al. 
(2007) found that influenza virus transmission is dependent on relative 
humidity and temperature and provided direct, experimental evidence to 
support the role of weather conditions in the dynamics of influenza. They 
found increased shedding of virus and enhanced transmission at 5°C when 
compared to 20°C. Research on the stability of RSV has been described by 
Rechsteiner and Winkler22, they prepared stable aerosols of RSV and kept them 
at different relative humidity. Virus recoveries were highest at high relative 
humidity and the stability of the aerosol was maximal at 60% relative humidity. 
This indicates that humidity indeed plays an important role and may affect 
transmission of the virus.  
 
Our study also highlighted a probable effect of cloud cover on RSV. To our 
knowledge, no other study has included this meteorological variable in the 
analysis. However, UV B has also been reported to predict respiratory syncytial 
virus activity.10 A possible explanation is that UV B radiance could interfere 
with the spread of RSV by inactivating the virus. UV B could also indirectly 
affect RSV activity by stimulating vitamin D on the outcome of RSV infection. A 
number of studies have indicated that vitamin D deficient children are at 
greater risk of having respiratory infections.23,24 In our study we did not include 
UV B, however one might expect some relation between UV B and cloud cover. 
Moise and Aynsley indicated that increasing cloud cover decreases the UV B 
because of the increase in the diffuse fraction of the radiation, and for the 
Netherlands it has been estimated that clouds generally decreased the UV 
radiation by 34% in the period 1998-2005.25,26 The direction of the relation of 
cloud cover corresponds to the inverse relationship of RSV activity and UV B 
that has been described by Yusuf et al.10 
 
One limitation of this study was the number of laboratories that reported data 
to ISIS; the number varied by year and thereby affected the number of tests 
performed for RSV diagnosis. In addition the methods used differed somewhat 
by laboratory, and did not include the most sensitive methods such as real-
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time polymerase chain reaction. Another limitation concerns the analysis of 
meteorological data as we chose to calculate weekly averages for most factors 
and modus for the wind direction. For some variables the values can differ 
considerably by day, e.g. wind direction, and our procedure may have reduced 
sensitivity to pick up the daily variation, and smoothing the effect of the 
weather variables on RSV. Finally, we used meteorological data from a central 
point, “the Bilt”, in the Netherlands, while using RSV data from predominantly 
the Southern and Eastern provinces of the country. However, we do not think 
that regional differences in weather would have affected our main outcomes, 
as distances are quite small in the Netherlands. In addition, although some 
minor daily variations in meteorological factors exist, we do not think that the 
slight differences in temperature and humidity have an effect on the study 
outcome, also because data was averaged to a weekly value.  
 
Factors other than meteorological conditions contribute to the spread of RSV. 
Meteorological factors in our study explained part (21%) of the variation in RSV 
cases; a driving factor for RSV activity is the immunity against RSV among the 
susceptible young population. Furthermore, weather factors might also have 
their effect through the behavior of the population when RSV is circulating. 
One practical explanation could be that in cold, rainy and cloudy days people 
stay inside and this causes more indoor crowding and transmission. In addition 
cold weather may also have an effect on the respiratory tract, as cold air may 
induce broncho-constriction.27,28 
 
The onset of RSV activity was very consistent for the eight winters and was 
around week 44, which is similar as described for the UK where the incidence 
of acute bronchitis and bronchiolitis in young children revealed a consistent 
increase in RSV activity during week 43 each year.29 Practical implications of 
our study relate to timing of RSV prophylaxis. The monoclonal antibody 
palivizumab offers protection against complications, and the first of the five 
monthly doses should be administered before onset of community RSV activity. 
Our findings of a consistent increase in RSV around week 44 in the Netherlands 
could be used for RSV prophylaxis, preferably combined with real-time RSV 
surveillance.  
 
The theoretical implications of our study are that relative humidity, minimum 
temperature and cloud cover are important predictors of RSV in the 
Netherlands and may be related to transmission of the virus. More 
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experimental research however is needed. In summary, we have found that 
onset of RSV activity is quite consistent in the Netherlands and that relative 
humidity, minimum temperature and cloud cover predict RSV activity in the 
Netherlands, with the effect of relative humidity being most consistent.  
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Abstract 
 
The laboratory performance of nucleic acid amplification techniques for 
respiratory syncytial virus (RSV) diagnosis was investigated in 25 laboratories 
across Europe. Our aim was to assess the laboratory performance of nucleic 
amplification tests and to explore what factors were related to the diagnostic 
performance. The panel consisted of nine samples containing RSV-A and/or 
RSV-B and one negative sample. Qualitative results and data on the type of 
assay and other laboratory characteristics were collected. An explorative 
analysis was carried out to investigate whether the laboratory characteristics 
were related to the diagnostic performance of the laboratories. The overall 
sensitivity for all laboratories was 88% (n=25; range 50-100). A correct score of 
93% (range 70-100) was observed for laboratories performing in-house real-
time PCR or nested PCR. Multilevel analysis showed that the type of assay 
(nested or real-time PCR vs. commercial test) was a significant factor 
(OR=8.39; CI95% 1.91-36.78) in predicting a correct result. The results for this 
external quality control study show that the overall performance of 
laboratories for RSV diagnosis in Europe is good and that real-time PCR is 
preferably used for RSV diagnostics. 
 
 
Introduction 
 
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract 
infections, particularly in infants and the elderly1-3 and leads to 
hospitalizations and excess mortality.4 Diagnostic RSV testing is usually 
performed on infants, elderly patients, and those with compromised immune 
systems, who have moderate to severe symptoms and lower respiratory tract 
involvement. RSV testing is also carried out to define and track the spread of 
RSV in the community.5  
 
Treatment of RSV infection is primarily supportive (minimizing pain and fever 
and easing breathing), however palivizumab, a monoclonal antibody, is 
available for RSV prophylaxis in preterm and high risk infants. Although 
antibiotic use is not indicated for bronchiolitis6 caused by RSV, a substantial 
proportion of RSV infected children (45%) received antibiotics.7 This 
inappropriate treatment can possibly be avoided by early laboratory diagnosis 
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of RSV infection.8 A rapid, valid and sensitive method for diagnosis is therefore 
important. 
 
One way to validate diagnostic tests is to participate in external quality 
assessment studies. External quality control for molecular detection has been 
reported for different pathogens including respiratory viruses.9-11 This type of 
assessment of laboratory diagnostics is important because assays continue to 
evolve and external quality control studies can contribute to further 
improvement of diagnostic methods. Rapid diagnostic RSV tests with a high 
sensitivity may result in improved patient care by decreasing length of 
hospitalization and directing specific therapy.12 
 
Over the last decade, nucleic amplification techniques (NATs) have become 
the new standard for virus detection and have moved into the mainstream of 
clinical testing.12 The major advantages of NATs compared to conventional 
techniques are the high sensitivity and speed.13,14 However, many NATs are still 
technically demanding and susceptible to contamination. Few factors11,15 have 
been described to help improve laboratory diagnostics and are related to the 
prevention of contamination and the choice of gene target. 
 
The European Influenza Surveillance Scheme (EISS) and the organization 
Quality Control for Molecular Diagnostics (QCMD) carried out a molecular 
external quality control study for RSV and compared the laboratory 
performance of NATs for RSV diagnosis of different reference laboratories in 
western and eastern Europe. This is the first study that explores whether 
laboratory characteristics are related to the quality of the diagnostic methods. 
The overall aim was to assess the laboratory performance of RSV molecular 
assays and to provide insights into laboratory specific factors that may be used 
to improve the quality of RSV molecular diagnostic methods. 
 
 
Materials and Methods 
 
Panel composition and participants 
The panel was distributed by the QCMD Neutral Office in Glasgow, United 
Kingdom. QCMD is specialized in the provision of External Quality Control 
Assessment schemes for a wide range of pathogens. The QCMD RSV panel 
consisted of nine coded samples containing RSV-A and/or RSV-B (ATCC strain 
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RSV-A-2; ATCC strain RSV-B/WV/14617/1985 wild type), and one sample 
negative for RSV (Table 6.1). The matrix was Dulbecco's Modified Eagle’s 
Medium and 10% Foetal Calf Serum. No quantitative data were available for 
the RSV panel, only sample dilutions; this procedure allows sample uniformity 
and reproducibility.  
 
Independent testing was performed by three laboratories in May 2006 and 
ensured the quality of the samples. The panels were distributed on dry ice by 
courier service to 33 laboratories (23 countries) on 27 June 2006. To ensure 
confidentiality, all participating laboratories received a code number. The 
selected participating laboratories were generally the national reference 
laboratories for influenza who take part in EISS.16,17  
 
Data collection 
Participants returned results to QCMD and completed a technical online 
questionnaire within six weeks after distribution of the panel. Information on 
the type of assay (commercial test, single PCR, nested PCR, real-time PCR), 
number of RSV tests performed per year (<500; ≥500), and the accreditation of 
the laboratory were collected through the QCMD technical questionnaire. 
Additionally, a questionnaire was sent electronically to the participating 
laboratories. This questionnaire included information on the following items: 
date of receipt of the panel (no delay, ≥ one week delay), training level of the 
laboratory staff (no training: “no training or doctoral studies”, training: 
“general training and experienced personnel”, PCR training: “specific PCR 
training”), target gene, whether the sample was tested for inhibition of the 
amplification reaction, and whether the participating laboratory was the 
national reference laboratory for RSV. It was hypothesized that these factors 
could be determinants of the performance score, and were therefore included 
in an explorative analysis to see whether these items were related to the 
performance of the laboratories. 
 
To investigate whether participants from different European regions achieved 
similar results, countries were divided into eastern and western European 
countries. On the basis of the United Nation Statistics Division the following 
countries were defined as “east”: the Czech Republic, Lithuania, Latvia, 
Poland, Romania, Slovenia, Slovakia, Estonia. Western European countries 
were: Austria, Denmark, Finland, France, Germany, Great Britain, Greece, 
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Ireland, Italy, Malta, Netherlands, Norway, Portugal, Spain, Sweden and 
Switzerland. 
 
Performance score 
A sum score was defined and used to analyze the performance of the 
laboratories. For each correct result on a positive or negative sample one point 
was given; no points were given in case of an incorrect result. The maximum 
score of the laboratory was 10 points. For data analysis the percentage of 
correct results was calculated. Typing of RSV was not performed by all 
laboratories and therefore typing results were not taken into account in 
calculating the performance score. Four respondents returned two datasets 
from two testing procedures of the same panel. We included the first 
submitted dataset in the analysis. Results for the first and second dataset were 
identical for three out of four respondents, one laboratory had a lower score 
for the second dataset (7 vs 10 points). The analyses were performed by the 
first author who was blinded for the laboratory code. 
 
Statistical analyses 
Statistical significance of differences in the mean performance score for 
different subgroups of variables was calculated using the Mann-Whitney U 
Test. This non-parametric test was used because the results for the 
performance score were skewed to the right and sample size was small. The 
Kruskall-Wallis Test was conducted to compare the performance scores for 
type of assay and training level. Significance was concluded when p<0.05. The 
program SPSS 14.0 was used for the analyses. 
 
Multilevel logistic regression was used to determine which laboratory 
characteristics were the best predictors of a correct result on each of the ten 
samples. We chose a multilevel analysis as the performance score for one 
sample is not independent of the performance score of another sample of the 
same laboratory; multilevel analysis takes into account such a hierarchical 
structure. Laboratories with missing data on the question of training level and 
the number of swabs tested in a year (n=7) were excluded from the multilevel 
analysis.  
 
Multilevel logistic regression analyses with a random intercept were performed 
using the second order PQL method.18 For the dependent variable (sample 
score: incorrect = 0; correct = 1) a logistic regression model was calculated 
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with the following laboratory characteristics as independent variables: type of 
assay (two dummy variables (“real-time PCR or nested PCR” and “single PCR”; 
reference category “commercial assay”), level of training (two dummy 
variables; reference category “no training”) and number of swabs tested (<500 
or ≥500). We combined the real-time and nested PCR in the multilevel analysis 
as they showed similar performance scores in the quality control assessment. 
All multilevel analyses were performed with MLwiN19, a statistical program for 
multilevel analyses. 
 
 
Results 
 
Participants 
The panels were distributed to 33 laboratories (23 countries). Eight 
participants did not return results for this program of which three withdrew 
officially. Reasons for the three laboratories to withdraw were: assay not 
available, resource issues and inconclusive results. The number of participating 
laboratories was 25 (76%) from 18 countries. Of the 25 participating 
laboratories 20 laboratories were from western Europe and five were from 
eastern Europe. 
 
Performance score 
The percentage of correct results on sample level ranged from 60% for sample 
9 to 100% for samples 1, 2, 6 and 7 (Table 6.1). The percentage correct results 
decreased correspondingly with decreasing sample concentration. One false 
positive test result (4%) was reported for the negative panel sample. The rate 
of false negatives was 14%. Lowest correct performance scores on sample level 
were observed for samples containing RSV-B only: 60% in sample 9, and 72% in 
sample 5. Laboratories that did not detect RSV-B in sample 9 were not able to 
detect RSV-B in sample 5 either. Two samples contained both RSV-A and RSV-B 
(samples 2 and 6), with RSV-B at a dilution of 2.0x10-4 for both samples (Table 
6.1). We compared the laboratories that reported RSV-B in these samples 
(n=14) to laboratories that did not detect RSV-B in the more diluted samples 5 
and 9 (1.0x10-5). Two laboratories detecting RSV-B in specimens 2 and 6 were 
not able to detect RSV-B in specimens 5 and 9, indicating a problem in the 
sensitivity of the assay performed in these laboratories.  
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Table 6.1: Panel composition and percentage correct results 
 
Sample 
code 
Sample content Target sample 
dilution 
Number correct 
results
Percentage correct 
results (N=25) 
1 RSV A 1.0x10-5 25 100% 
2 RSV A and B 2.0x10-5 / 2.0x10-4 25 100% 
3 RSV A 1.0x10-6 19 76% 
4 RSV Negative   24 96% 
5 RSV B 2.0x10-5 18 72% 
6 RSV A and B 2.0x10-5 / 2.0x10-4 25 100% 
7 RSV A 1.0x10-5 25 100% 
8 RSV A 2.0x10-6 21 84% 
9 RSV B 2.0x10-5 15 60% 
10 RSV A 2.0x10-6 22 88% 
 
 
Performance and type of assay 
The performance for the individual laboratories is presented in Table 6.2. 
Eleven laboratories reported 100% correct results. The overall mean sensitivity 
was 88% (range 50-100). The majority (22 out of 25) of laboratories used an in-
house assay. In particular real-time PCR and nested PCR assays provided the 
highest performance scores (93% correct score; range 70-100) and were used in 
19 laboratories. Three laboratories used commercial assays and the percentage 
correct results, representing the overall score of the laboratory, ranged from 
50% to 80%. Laboratories that had a performance score of 80% or lower usually 
had difficulty in the detection of RSV-B (Table 6.2).  
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The gene target for amplification varied between the laboratories, though 
most laboratories used the nucleoprotein gene as gene target, singly or in a 
combination with another gene (Table 6.3). To test whether a combination of 
target genes showed a better performance than a single target gene, we 
performed the Mann-Whitney U test. The performance of laboratories that 
used a combination of target genes (n=4) did not differ significantly (p=0.076) 
from laboratories that used one target gene (n=19). 
 
 
Table 6.3: Performance score by target gene 
 
Target gene (N) Percentage correct result (%) 
 median range 
N/G  1 100   
N/P 3 100 90-100 
N or NS-1* 1 90   
F 5 90 70-100 
N 11 90 50-100 
L 1 80   
G 1 60   
 
* N for RSV A; NS-1 for RSV B. 
Abbreviations: N, nucleoprotein gene; P, phosphoprotein gene; G, surface glycoprotein gene; 
L, polymerase gene; F, surface fusion protein; NS-1, non-structural protein 1. 
 
 
Performance and laboratory characteristics 
The laboratory performance score is presented for the different laboratory 
characteristics in Table 6.4. The Mann-Whitney U Test or Kruskall-Wallis Test 
was conducted to compare the performance for the different laboratory 
characteristics. Statistically significant differences in means were observed for 
the type of assay (“commercial”, “single PCR”, “nested PCR”, and real-time 
PCR”: p=0.026). These results suggest that there is a difference in 
performance scores across the different types of assay, with the highest 
performance scores for laboratories using real-time PCR and nested PCR.  
 
No significant differences were observed for the performance score across 
different level of training (p=0.080) and the number of swabs tested (p=0.086). 
Furthermore, none of the other laboratory characteristics had an impact on 
the laboratory performance (Table 6.4). 
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Table 6.4: Percentage correct result for the different laboratory 
characteristics 
 
Laboratory characteristics  N  Percentage correct result (%) 
  median range p-value 
Type of assay         
Commercial 3  60 50-80 0.026 
Single PCR 3  80 70-90   
Nested PCR 9  100 70-100   
Real-time PCR 10  100 70-100   
Number of swabs tested        
<500 9  90 50-100 0.086 
>500 10  100 70-100   
Laboratory accreditation         
No 7  100 50-100 0.723 
Yes 12  90 70-100   
Delay in receipt panel         
No delay 15  100 60-100 0.199 
≥ One week delay 10  85 50-100   
Training level         
No training 5  70 50-100 0.080 
Internal training 13  90 70-100   
PCR training 5  100 90-100   
Samples tested for inhibition       
No 18  90 50-100 0.944 
Yes 6  95 70-100   
National reference laboratory      
No 17  90 50-100 0.539 
Yes 5  90 80-100   
Region        
East 5  100 50-100 0.567 
West 20  90 60-100   
 
 
Multilevel analysis 
To study the effect of each of the relevant variables corrected by other 
variables on the performance score, multilevel logistic regression analysis was 
performed (Table 6.5). The data was analyzed on sample level, with 10 
samples for each laboratory (N=18). We included the following variables in the 
model: type of assay, level of training and the number of swabs tested in a 
year in the model. The results showed an OR of 8.39 (CI95%: 1.91-36.78) for the 
in-house PCR (nested or real-time PCR) versus commercial PCR. The other 
variables did not predict independently a good performance.  
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The different types of assay were also assessed separately and compared using 
contrast test for fixed effects in MLwiN resulting in a chi-square test statistic. 
A significant difference in performance score between commercial and nested 
PCR (X2= 12.92; p<0.001) and between commercial and real-time PCR (X2 
=14.62; p<0.001) were observed. Additionally significant differences were 
observed between single PCR and nested PCR (X2 = 3.86; 0.02<p<0.05) and 
single PCR and real-time PCR (X2 = 4.82; 0.02<p<0.05). 
 
 
Table 6.5: Multilevel analysis (N=10 tests; N=18 laboratories): Predictive 
factors for a correct result on sample level adjusted for the type 
of assay, level of training and number of swabs tested in a year 
 
  OR CI (95%) 
Type of assay: single PCR* 2.21 0.51 - 9.67 
Type of assay: nested or real time PCR* 8.39 1.91 - 36.78 
Level of training: internal** 1.15 0.34 - 3.96 
Level of training: PCR** 2.31 0.22 - 24.36 
Number of swabs tested 0.87 0.25 - 3.00 
 
*  Dummy variable, reference category = commercial test. 
**  Dummy variable, reference category = no training. 
OR: Odds ratio. 
CI : Confidence interval. 
 
 
Discussion 
 
The results of this study underscore that RSV testing at participating 
laboratories in eastern and western Europe is generally good, with exception 
of five laboratories that had a correct score of 50% to 70%. We have found a 
good performance of molecular assays for RSV-A detection, and a somewhat 
lower performance for RSV-B. To our knowledge, this is the first study that 
explores whether laboratory characteristics can predict the performance 
score. We found that the type of method (real-time PCR or nested PCR versus 
commercial test) was a significant factor in predicting a correct result. 
However, it is important to be aware of the risk for contamination problems in 
nested PCR.20 In addition to the type of method, our study suggests that 
training and the use of a combination of target genes could also enhance the 
performance, even though results were not statistically significant. Repeating 
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this study in a large number of laboratories might result in the establishment 
of additional independent factors impacting the performance. 
 
Possible reasons for a lower detection of RSV-B may be due to an actual lower 
sensitivity of the tests, which was observed for commercial and single PCR in 
particular. Commercial assays showed a lower performance, but since only 
three laboratories used this type of assay further research is required to 
investigate the real sensitivity of these and other commercial methods. A 
limitation of the study was the number of non-respondents; eight participants 
did not report results to QCMD. One of the laboratories withdrew because of 
inconclusive results and this may indicate problems in the testing and a bad 
performance. The results of the participating laboratories may therefore not 
be completely representative for all laboratories in Europe. Additionally, not 
all questions in the questionnaires were completed for all laboratories and 
these laboratories were therefore excluded from the multilevel analysis. The 
power of the study was determined by the number of participating 
laboratories, resulting in relatively wide confidence intervals in the multilevel 
analyses.  
 
Another limitation of this study was that no clinical isolates were used and 
therefore only the technical sensitivity could be determined. Data on the 
absolute virus quantity in the samples were not available, only dilution factors, 
which were used as a semi-quantitative measure. The good results for in-house 
PCR tests probably reflect the good sensitivity of the test. However it may be 
possible that the primers of the molecular assays matched well with the ATCC 
strains of the panel, but whether this is also true for the actually circulating 
viruses that are present in clinical samples, could not be assessed in this study.  
 
The majority of molecular assays that were available were research and 
clinical “in-house assays” utilizing PCR as the primary method of amplification. 
In our study, only three laboratories used a commercial test and these tests 
generally had a lower performance score than the in-house assays. A study 
carried out by Templeton et al.10, included only one (other) commercial test 
for RSV, and had a correct score of 50%, which seems comparable to our 
results, but the number of commercial tests is small and the performance 
varies by type of test. Commercial tests generally performed well compared to 
in-house assays for other pathogens, as has been described for Chlamydia 
trachomatis and Mycobacterium tuberculosis, and for these pathogens the 
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number of laboratories that use commercial assays is substantial.9,21 In our 
study, one false positive was detected in the negative sample, and this finding 
is similar to results from other quality control programs for virus 
detection.10,11,22 
 
In terms of clinical implications, it is important that the diagnosis of RSV 
infection is made quickly. In practice quick RSV tests are also used and these 
have the advantage of having available results within 20-30 minutes. The 
sensitivity of these type of tests seem reasonable23, but is lower when 
compared to other methods such as real-time and nested PCR.  
 
This study has shown differences between laboratory characteristics, with only 
the type of assay explaining differences in test performance. The performance 
score for laboratories located in eastern Europe did not differ from the score 
of laboratories located in western Europe. Currently, many laboratories in 
eastern Europe carry out NATs, while molecular assays were not regularly 
performed five years ago.24 Even though molecular assays are used for a few 
years in these laboratories they performed well in this external quality control 
assessment.  
 
This study is the first step in providing insight in laboratory specific factors 
which can be used to improve the quality of RSV molecular diagnostics. The 
comparison of laboratory performance in diagnostic testing through external 
quality control studies is very important and allows the investigation of factors 
that affect the performance.  
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Abstract 
 
In this study, we present the multiple detection of respiratory viruses in 
infants during primary respiratory illness, investigate the sensitivity of nasal 
swabs and nasopharyngeal aspirates and assess whether patient characteristics 
and viral load played a role in the sensitivity. Healthy infants were included at 
signs of first respiratory tract infection. Paired nasopharyngeal aspirates and 
nasal swabs were collected. Real-time polymerase chain reaction was carried 
out for eleven respiratory pathogens. Paired nasopharyngeal aspirates and 
nasal swabs were collected in 98 infants. Rhinovirus (n=67) and respiratory 
syncytial virus (n=39) were most frequently detected. Co-infection occurred in 
48% (n=45) of the infants. The sensitivity of the nasal swab was lower than the 
nasopharyngeal aspirate in particular for respiratory syncytial virus (51% vs. 
100%) and rhinovirus (75% vs. 97%). Sensitivity of the nasal swab was strongly 
determined by the cycle threshold value (p<0.001). Sensitivity of the swab for 
respiratory syncytial virus, but not rhinovirus, was 100% in children with severe 
symptoms (score≥11). It is concluded that for community based studies and 
surveillance purposes the nasal swab can be used, though the sensitivity is 
lower than the aspirate in particular for the detection of mild cases of RSV 
infection. 
 
 
Background 
 
Respiratory viruses are a common cause of illness in children, in particular 
during their first years of life and may lead to more severe morbidity and 
hospitalisation.1-4 Different types of specimen are available for viral diagnosis. 
The nasopharyngeal aspirate (NPA) has been considered the best sampling 
technique, but is more invasive and results in significantly more distress of the 
infant than a nasal swab (NS).5 A number of studies have compared the 
sensitivity of NPA with nasopharyngeal swabs6, nose-throat swabs7 and NS.5,8-10 
Generally conventional techniques such as viral culture and antigen detection 
methods were used. The use of real-time polymerase chain reaction (PCR) may 
overcome differences in sensitivity for respiratory viruses as a result of 
specimen type.7  
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Limited data is available on the comparison of these sampling methods 
combined with real-time PCR. It was observed that nose-throat swabs are a 
less invasive diagnostic technique with adequate sensitivity for use in 
outpatient and large community-based settings in children.7 However, no tests 
were performed for rhinovirus, while this virus commonly infects infants.11 The 
aim of this study was to present the detection of common respiratory 
pathogens in infants during primary respiratory illness, to investigate the 
sensitivity of NS and NPA, and assess the role of patient characteristics and 
viral load in the sensitivity of either sampling method. 
 
 
Study Design 
 
Study Cohort 
The study is part of the Netherlands Amnion Fluid Study of the Utrecht 
University Medical Centre (UUMC), the Netherlands.12 Healthy infants were 
included at birth, and were at risk for primary respiratory infection until the 
age of one year. The data collection and episode sampling stopped one year 
after birth. From April 2006 to April 2008, including two winter seasons, paired 
NPA and NS specimens were obtained from 98 infants. Parents were instructed 
to notify the clinical staff within 24 hours after onset of symptoms. Clinical 
staff visited the child within 36 hours and the history of illness was taken by a 
standardized questionnaire. Symptoms were scored, according to Gern13, with 
points presented in parentheses: fever (> 38°C)(1); cough, mild(1), 
moderate(2), severe(3); rhinorrhea, mild(1), moderate to severe(2); 
hoarseness(1); duration of illness > 4 days(1); apnoea(3); wheezing(5); 
retractions(5); tachypnea(5); cyanosis(5). Mild, moderate and severe infection 
were defined as sum scores 0-4, 5-10 and 11 and higher, respectively. Specially 
trained clinical staff obtained paired NS and NPA.  
 
Collection of specimens 
The NPA was obtained by use of an infant mucus extractor (Vygon). Both 
nostrils were suctioned. In addition a NS was collected, samples were collected 
from one nostril and one from the hard palate using separate cotton-tipped 
swabs (Infant Mucus Extractor, Vygon Pharmaceutiques, Ecouen, France). The 
two swabs were then inserted in one vial containing 2 ml of virus transport 
medium (gly medium). 
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Real-time PCR 
Semi-quantitative real-time PCR was conducted on both NS and NPA for RSV, 
rhinovirus, human metapneumovirus, adenovirus, coronavirus, influenza, 
parainfluenza virus type (type 1,3), parainfluenza (type 2,4), bocavirus, 
Mycplasma pneumoniae, and Chlamydia pneumoniae. Nucleic acids were 
extracted using the QIAamp DSP virus kit (QIAGEN, Valencia, CA). Each sample 
was eluted in 200 μl buffer. cDNA was synthesized by using MultiScribe reverse 
transcriptase (RT) and random hexamers (both from Applied Biosystems, Foster 
City, CA, USA).14 Each 100 μl reaction mixture contained 60 μl cDNA mix and 40 
μl of eluted RNA. After incubation for 10 minutes at 25°C, RT was carried out 
for 30 minutes at 48°C, followed by RT inactivation for 5 minutes at 95°C.14 
Samples were assayed in a 50 μl reaction mixture containing 20 μl (c)DNA, and 
30 μl mix of the forward and reverse primers and probes. All samples had been 
spiked before extraction with an internal control virus (murine 
encephalomyocarditis virus [RNA] and phocine herpes virus [DNA]). The 
amplification and detection were performed by use of the ABI Prism 7700 
sequence-detection system; 2 min at 50°C to acquire optimal AmpErase UNG 
activity and 10 min at 95°C to activate AmpliTaq Gold DNA polymerase, 
followed by 45 cycles of 15s at 95°C and 1 min at 60°C.15 Primers and probes 
for real-time PCR detection of RSV, influenza virus, para-influenza virus and 
adenovirus are available by van de Pol et al.16 and real-time PCR were 
performed as described previously17-19.  
 
Statistical analysis 
Similar to previous studies, a consensus standard was used to assess sensitivity 
of each testing method: a positive result in either NPA or NS was considered as 
gold standard for presence of a pathogen and used to calculate the sensitivity 
of the NPA and NS for detection of the respiratory pathogens. Chi-square test 
was used and a logistic regression analysis was performed. The outcome 
variable was defined as the sample being positive. Variables inserted in the 
model were age, gender, symptom score, and multiple virus detection. 
Statistical significance was concluded if the p-value was <0.05. The statistical 
analyses were performed in STATA 10.0 (StataCorp LP, TX USA).  
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Results 
 
A total of 163 respiratory pathogens were identified in 94 children. The 
majority of children (73.5%) were ill for less than 4 four days at the time of 
sampling. The median age at primary infection was 104 days (range 33-269) 
and the median score of symptoms was 3, indicating a mild illness (Table 7.1). 
In all children with an illness of five days or longer, one or more pathogen was 
detected. 
 
 
Table 7.1: Characteristics of infants during first airway infection 
 
Characteristics All infants 
(n=98) 
Rhinovirus detected 
(n=67) 
RSV detected (n=39) 
Median age in days (range)  104 (33-269) 99 (33-269) 115 (51-269) 
Median days of illness at 
time sampling (range) 3.5 (2-31)
c 4 (2-16) 4 (2-12) 
% Male  58% 60% 62% 
    
Symptoms    
Rhinorrhea    
None 15% 15% 18% 
Mild 55% 58% 46% 
Moderate-severe 30% 27% 36% 
Cough    
None 17% 18% 5% 
Mild 36% 46% 28% 
Moderate 37% 30% 46% 
Severe 10% 6% 21% 
Wheezing a 8% 6% 10% 
Fever >38°C 17% 12% 23% 
Hoarseness 28% 22% 31% 
Apnea b 3% 2% 5% 
Cyanosis 1% 0% 3% 
Retractions 6% 3% 5% 
Tachypnea 20% 16% 28% 
Median sumscore (range) 3 (0-25) 3 (0-15) 4 (1-25) 
0-4 64% 72% 56% 
5-10 25% 22% 26% 
>10 11% 6% 18% 
 
a reported by parents; b N=97, c duration of illness: IQR = 3-5. 
Values represent percentages, unless indicated otherwise. 
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Multiple pathogens in half of the children 
In 49 children (50%) one pathogen was detected: 29 rhinovirus, 11 RSV, 4 
coronavirus, 2 hMPV, 2 parainfluenza virus type 2 and 4 and 1 bocavirus. In 
twenty-five children two pathogens were detected, of which 24 (96%) were 
rhinovirus with RSV. In 20 children more than two pathogens were detected 
during the first episode of respiratory symptoms (three pathogens: n=17; four 
pathogens: n=2; five pathogens: n=1). Co-infection rates by pathogen were: 
rhinovirus (57%), hMPV (60%), RSV (72%), coronavirus (71%) and bocavirus 
(91%).  
 
Sensitivity of nasal swab is lower than the aspirate for RSV and rhinovirus 
Rhinovirus was found most frequently (n=67), followed by RSV (n=39) and 
coronavirus (n=14) (Table 7.2). No influenza viruses and parainfluenza type 1 
and 3 viruses were detected. Sensitivity for detecting any pathogen of the NPA 
was 92% (CI95% 86.7-95.7), whereas the sensitivity of the NS was lower at 67% 
(CI95% 59.1-74.0). For the detection of RSV and rhinovirus the sensitivity of the 
NS was lower than the NPA (Table 7.2). 
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Sensitivity of nasal swab depends on viral load 
Sensitivity values of the NPA and NS were investigated in more detail for 
rhinovirus and RSV (Table 7.3). For children with a low symptom score the 
sensitivity of the NS was lower than the NPA. The NS had a lower sensitivity 
than the NPA for the 30-40 CT values. To assess whether the sensitivity of the 
NS differed by age group, gender, multiple pathogens, symptom score and CT-
value, chi-squared tests were performed. The sensitivity of the NS for 
detection of RSV was related to the symptom score (p=0.001), and the 
sensitivity of the NS was related to the CT values for both RSV and rhinovirus 
(p<0.001).  
 
In the logistic regression analysis age and gender did not significantly predict 
the detection of RSV or rhinovirus. Symptom score predicted RSV detection in 
both the NPA (OR: 1.21; CI95% 1.07-1.39) and the NS (OR: 1.28; CI95% 1.12-1.48), 
while an inverse relationship was observed for symptom score and rhinovirus 
detection in the two samples (OR: 0.87; CI95% 0.78-0.98). The presence of more 
than one pathogen predicted RSV (OR: 8.98; CI95% 3.03-26.7) or rhinovirus 
detection (OR: 3.66 CI95% 1.33-10.08) in the NPA. When the same analysis was 
performed as a backwards regression with p<0.2, results did not change. 
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Discussion 
 
This study presents that the proportion of infants where a respiratory pathogen 
detected was high (96%), and co-infections were common. In twenty children 
more than two pathogens were detected during the first episode of respiratory 
symptoms. Co-infections were observed frequently for RSV (72%), coronovirus 
(71%) and bocavirus (91%) in particular.  
 
High rates of co-infection in young children have been described recently for 
childhood pneumonia in particular in children aged less than 12 months20, and 
in children hospitalized with acute respiratory tract infection.21,22 The most 
frequently detected virus was RSV followed by human bocavirus, and 
rhinovirus.21,23 A common combination has been reported to be RSV and 
bocavirus.21 Even though high occurrence of co-infections has been reported, 
ranging from 14-16%21,22 to 27%20, our study presents an even higher rate of co-
infection. A possible explanation for this high co-infection rate may be related 
to the sampling of both nostrils for the NPA. Human bocavirus is a newly 
identified virus and has been detected in respiratory tract secretions in 
patients with acute respiratory symptoms in 2 to 19% of the samples.24 Co-
infection with another virus has been observed in 40% of the bocavirus-positive 
children.25 The frequent associations of bocavirus with other respiratory 
viruses might be explained by the persistence of bocavirus in the respiratory 
tract.25 
 
Furthermore, we investigated the sensitivity of NPA and NS tested by a real-
time PCR method. The sensitivity of the NPA was 92%, while for the NS this was 
67%. In particular for the detection of rhinovirus and RSV, the NS had a lower 
sensitivity (75% and 51% respectively) compared to the NPA (97% and 100%). 
Sensitivity of the NS for RSV was 100% for children with high symptom scores. 
For both RSV and rhinovirus, viral load, indicated by the CT value, was the 
major determinant of sensitivity of NS in a dose-dependent fashion. Symptom 
score predicted RSV detection in both the NPA and the NS, while an inverse 
relationship was observed for symptom score and rhinovirus detection in the 
two samples.  
 
The use of a swab has been considered as a suitable replacement in 
community-based research or epidemiological studies. The major advantage of 
a swab is that collection is less painful, and more convenient than an aspirate 
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as no additional devices are needed.5 These factors may outweigh some 
reduction in sensitivity. The advantage of molecular methods in the detection 
of respiratory viruses has been reported26,27 and Lambert et al. reported that 
using these methods seemed to overcome the previously observed sensitivity 
reduction when less invasive specimens were combined with the conventional 
laboratory methods.7 With the recently developed flocked swabs, sensitivity is 
even further improved and the flocked swabs have the advantage of being 
rapid, and less traumatic for paediatric patients.28 However, the sensitivity of 
the flocked swab in outpatient respiratory tract infection may be lower than in 
hospitalized patients. Further studies are required considering different types 
of swabs and patient populations, and should test for a broad spectrum of 
respiratory pathogens. 
 
Our findings demonstrated a lower sensitivity of the NS, in particular for RSV. 
Similar results were reported in other studies where conventional, non-
amplification based-methods were used.8,9 Lambert et al. did not test for 
rhinovirus, and this was the most frequently detected virus in our study and 
elsewhere.11,29 No influenza detections were found in our study. This is not 
explained by sampling bias, because most swabs were taken during the winter 
season, during which both RSV and influenza had their peak incidence. A 
possible reason may be related to the patient population and the small 
population size. The study performed by Bueno et al. showed similar results 
with rhinovirus and RSV being most frequently detected.29 
 
There were a number of limitations of this study. Firstly, one limitation was 
the timing of sampling. For five cases sampling occurred 10 days after the 
onset of illness. Since viral shedding of RSV is highest between days 0 and 6 
sampling should preferably occur in this period.30 The high proportion of 
positive samples however indicates this effect was not a major drawback of 
this study. Secondly, in this study pain and discomfort of the collection of the 
samples was not assessed, but other studies provided reference for this.5 
Finally, it is unknown whether the order of obtaining the specimens may have 
resulted in a lower detection rate in NS. It is possible that by suctioning both 
nostrils for the NPA the secretions with virus or viral nucleic acids were 
reduced. This corresponds with the finding that few mild cases were detected 
with the NS, as sensitivity of the NS dropped with lower symptoms score and 
higher CT values. Because the order and nature of the sample collection was 
slightly different from the study performed by Lambert et al., the sensitivity of 
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the NS may be an underestimate, and caution needs to be taken when 
interpreting the NS sensitivity.  
 
RSV and rhinovirus were commonly detected in infants during primary 
respiratory infection, and co-infections occurred in about half of the children. 
The sensitivity of NPA was higher than NS, in particular for detection of RSV 
and rhinovirus. Although sensitivity of a method is important, one must also 
take into account the advantages that different sampling methods offer. The 
great advantage of the NS is that this method can be performed in outpatient 
settings without needing special devices, is less costly and causes less distress 
in the patient than the NPA. Although there is a reduction in sensitivity for RSV 
particularly in infants with mild symptoms, the NS is convenient for sampling 
patients in community studies and can be used for surveillance purposes. 
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Summary and general discussion 
 
 
This final chapter provides an overview of findings presented in this thesis, 
methodological considerations, the implications of the findings and 
recommendations for future research. 
 
The aim of this thesis was to improve surveillance and diagnostic methods of 
respiratory syncytial virus (RSV) in Europe. We have investigated: 
a. which countries collect RSV data and whether these data are being reported 
timely, 
b. the occurrence of RSV and the relation with meteorological factors, 
c. what diagnostic methods are used to detect RSV, and 
d. what factors relate to the sensitivity of a diagnostic RSV test. 
 
 
Summary of the main findings 
 
Surveillance of RSV 
In Chapter 2 we reported on an investigation of the virological data collection 
for influenza and whether RSV data were collected in 19 countries1. This study 
was carried out in June 2002. We have found that the laboratory techniques 
for the detection of influenza were heterogeneous, and specimen collection 
and transport procedures were similar. Most national influenza surveillance 
networks collected nasal and throat swabs and ELISA, HAI and PCR were 
generally used for typing and subtyping of influenza viruses. In Western Europe 
PCR was regularly used, while in Eastern Europe, ELISA was predominantly 
used. Thirteen out of nineteen countries tested the specimens for RSV as well 
and some for other respiratory viruses. The substantial number of countries 
that tested for RSV indicates that more detailed information on RSV activity in 
Europe can be provided.  
 
In Chapter 3 we presented the data reporting and timeliness of influenza and 
RSV data for three countries in Europe.2 Timely data are important in order to 
function as an early warning system for outbreaks of respiratory disease. Data 
on both RSV and influenza were provided timely (i.e. within 1 week after 
detection) and country-specific data showed that RSV contributed considerably 
to the burden of influenza-like illness in particular in the United Kingdom. We 
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formulated the following recommendations for RSV surveillance: 1) Specimens 
collected as part of an influenza surveillance programme should also be tested 
for RSV; 2) Both combined nose-throat swabs and nasopharyngeal aspirates are 
acceptable for RSV diagnostics; 3) The application of molecular techniques 
such as real-time PCR in the diagnosis of respiratory disease has been 
demonstrated and we advocate this technique for RSV detection; 4) Further 
develop standardized methods and laboratory techniques; 5) Consider the 
development of a sentinel approach of representative hospitals; 6) Integration 
of RSV surveillance in countries joining the surveillance system alongside 
influenza. 
 
Subsequently we presented the progress in the surveillance of RSV in Europe 
over the period 2001-2008 in Chapter 4.3 In 2003, an RSV Task Group was 
established within the surveillance network to explore the possibility to design 
a comprehensive RSV surveillance scheme. In this Chapter we present steps 
forward that were made for the recommendations that were introduced in 
Chapter 3. We found that the number of European countries testing specimens 
for RSV increased from six to fourteen and respiratory specimens from nose 
and/or throat were generally used for detection of influenza and RSV. A total 
of 25 laboratories performed molecular testing for diagnosing RSV and 
participated in a quality control assessment for RSV with an overall good 
performance.4 Limited progress was achieved for standardizing methods and 
for the development of a sentinel surveillance system for RSV of representative 
hospitals. Four out of ten new countries started reporting RSV detections in 
addition to influenza in the period 2004-08. 
 
Seasonal variation of RSV and the role of the weather conditions 
The seasonal pattern of RSV and the role of the weather conditions in the 
Netherlands was investigated and presented in Chapter 5. We found that the 
onset of RSV activity occurred around week 44, peaked around week 52, and 
was quite consistent for the study period (8 winters). This information is useful 
for the timing of the palivizumab antibody prophylaxis. The minimum 
temperature was variable for the different winter seasons but a generally 
lower temperature was observed around the peak activity. The relative 
humidity, minimum temperature, and cloud cover were significantly correlated 
with the weekly number of RSV cases. This finding was observed for different 
time lags, but the r-value decreased with increasing time lag for relative 
humidity and cloud cover. 
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In multiple linear regression analysis at least one of the meteorological 
factors, minimum temperature, relative humidity and cloud cover, was 
significantly associated with RSV activity in seven out of eight winters seasons. 
For all seasons together, the relation of temperature with RSV activity was 
negative, indicating more RSV activity when the temperature decreased. A 
positive relation was observed for relative humidity and to some extent for 
cloud cover, indicating more RSV activity when the relative humidity or cloud 
cover increased. Our data showed that relative humidity, minimum 
temperature and cloud cover were important predictors of RSV activity for 
different time lags in the Netherlands, with the effect of relative humidity 
being most consistent. 
 
Laboratory testing for RSV 
Chapter 6 presents the findings of a European quality control study for RSV 
detection and highlights the impact of laboratory characteristics.4 A panel 
consisting of nine coded samples containing RSV-A and /or RSV B and one 
negative sample was evaluated in 25 laboratories across Europe. The overall 
mean percentage of correct results was 88%, and ranged from 50% to 100%. 
The percentage correct results decreased in correspondence with decreasing 
sample concentration. The type of assay (nested or real-time PCR vs. 
commercial tests) was identified as a significant factor (OR 8.39; CI95% 1.91-
36.78) in predicting a correct result, which indicates that nested or real-time 
PCR performed better than the commercial assays. 
 
In Chapter 7 we reported on a study that assessed the sensitivity of real-time 
PCR for eleven respiratory pathogens in two types of specimens. Healthy 
infants were included at signs of first respiratory tract infection. The study 
period was from April 2006 to April 2008 including two winter seasons. Paired 
nasopharyngeal and nasal swabs were collected in 98 infants. In 94 infants one 
or more pathogen was detected. Rhinovirus was found most frequently (n=67), 
followed by RSV (n=39) and coronavirus (n=14). The overall sensitivity of the 
nasopharyngeal aspirate was 92%, and for the nasal swab the sensitivity was 
67%. The sensitivity of the nasal swab was similar or higher to the 
nasopharyngeal aspirate for parainfluenza type 2 and 4, Mycoplasma 
Pneumoniae and Chlamydia Pneumoniae. The nasal swab performed less well 
than the nasopharyngeal aspirate for the other respiratory pathogens, with the 
difference for RSV and rhinovirus being most distinct. For both RSV and 
rhinovirus detection the viral load, indicated by the CT-value, was the major 
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determinant of sensitivity of the nasal swabs. Age and gender did not predict 
the detection of RSV or rhinovirus. A higher symptom score was related to RSV 
detection in both the nasopharyngeal aspirate and nasal swab, and a lower 
score was related to rhinovirus detection.  
 
Methodological considerations 
The Chapters in this thesis are based on different sources of data. The 
surveillance-related data (Chapters 2-4) were descriptive and largely based on 
sentinel surveillance data. In Chapter 5, weekly RSV cases reported by the 
Infectious diseases Surveillance Information System (ISIS) were used and 
weather data was obtained from the Royal Netherlands Meteorological 
Institute (KNMI). Chapter 6 described a quality control assessment for the 
detection of RSV for 25 laboratories and assessed laboratory characteristics as 
determinant of outcome of the test. Finally, in Chapter 7 real-time PCR 
methods were used to detect respiratory pathogens in infants during primary 
respiratory infection, using two types of respiratory specimens. 
 
Limitations methodology 
We will first describe the limitations concerning data obtained by surveillance. 
Surveillance is used to provide an early warning function or outbreak 
detection. The basis of the surveillance platform presented in this thesis is 
integrated clinical and virological data collection from sentinel GPs. In sentinel 
surveillance, standard case definitions and protocols must be used to ensure 
validity of comparisons across time and sites despite lack of statistically valid 
sampling.5 Although the European Influenza Surveillance System was 
established in 1996 and has made efforts in harmonizing the surveillance, the 
case definitions used by individual countries are heterogeneous and 
methodologies differ somewhat by country.6 This is one limitation that makes 
between-country comparisons difficult.  
 
Another important limitation concerns the fact that an influenza surveillance 
network was used to report data on RSV. The case definitions for influenza-like 
illness and acute respiratory illness have been established for influenza and 
not for RSV. But since RSV infection may be difficult to distinguish from 
influenza7, the influenza-case definitions may also be applicable for RSV as 
well, as long as no RSV-specific definition has been defined. Anyway, it is 
difficult to apply rigid guidelines across all age groups and patients that 
consult in different phases in their illness.8 
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In particular young children, aged 0-4 years, visit their general practitioner for 
respiratory complaints. However, the sampling of these patients may actually 
be underrepresented in some countries2, as doctors may be reluctant to swab 
infants and regular swabs may not be suitable for small children. On the other 
hand, non-sentinel hospitals predominantly report the detection of RSV in 
young children. One needs to take this into account when interpreting the RSV 
data from different sources. 
 
For the study on the role of meteorological factors with RSV, some limitations 
can be posed. Data were available for the Southern and Eastern parts of the 
Netherlands. Additionally, the number of laboratories differed by season and 
the weather data were collected from one central point in the country. 
Furthermore, the effect of meteorological factors was less obvious when data 
were assessed by individual winter season, but this may be due to the low 
number of RSV cases reported in some winters. It would be interesting to 
investigate whether the contribution of temperature and humidity to RSV 
activity can also be observed for other countries in Europe.  
 
Limitations for the quality control study for RSV are: 1) the number of 
participating laboratories, with 25 out of 33 laboratories participating, and 2) 
the use of ATCC strains instead of clinical samples. Data on the absolute virus 
quantity in the samples were not available, only dilution factors, which were 
used as a semi-quantitative measure. However, the good results for in-house 
PCR tests probably reflect the good sensitivity of the test. Finally, in Chapter 7 
we compared the sensitivity of molecular assays for two types of respiratory 
specimens. We observed a very high percentage of positive specimens (96%), 
and a co-infection rate of 48%. While it is important for a diagnostic test to 
have a high sensitivity, the most recent PCR techniques may also pick up 
irrelevant viral infections. With multiple viral pathogens detected, the 
aetiology of respiratory illness is troubled. 
 
Strengths surveillance 
One of the strengths of influenza and RSV surveillance described in this thesis 
is the integrated clinical and virological surveillance model.9 In this model 
sentinel general practitioners usually covering 1-5% of the population report on 
the occurrence of influenza-like illness and/or acute respiratory infection. 
From a proportion of these patients a respiratory specimen is obtained and 
sent to the laboratory for diagnosis. A great advantage of this sentinel 
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surveillance system is the availability of a population denominator which 
allows to present age-specific rates of influenza-like illness and/or acute 
respiratory infection. The large number of countries that have been working 
together and sharing information allowed to present information on the 
circulation of influenza and RSV in a large number of European countries.10  
 
In addition to the integrated sentinel data, non-sentinel data are collected for 
surveillance. The non-sentinel data are generally derived from hospitals. The 
combination of the two data sources provides a full picture of respiratory 
infections in both the community and the hospital setting. Another strength of 
surveillance is the timeliness of the data collection. Countries enter 
surveillance data into an internet-based platform since 1996.11 Data on 
influenza and RSV are timely published in a weekly electronic bulletin with a 
delay of one week (Figure 8.1). Surveillance of both influenza and RSV, which 
circulate in the community around the same time of the year, facilitates to 
unravel the impact of these respiratory viruses.  
 
 
Figure 8.1: Data reporting and data presentation in a weekly electronic 
Bulletin. 
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Implications of the findings 
 
Monitoring respiratory syncytial virus 
Effective surveillance is essential to keep on top of winter illnesses and routine 
respiratory virus surveillance can predict their arrival, monitor their 
progression and recommend appropriate advice on how to contain them.8 For 
example, preventive measures can be taken and/or evaluated in neonatal 
wards and the RSV surveillance can be useful for the timing of palivizumab 
prophylaxis. In the US, regional RSV surveillance has been already 
implemented to support clinical decision making for prophylaxis in premature 
infants12,13 and the data obtained through RSV surveillance has been useful in 
understanding the seasonal and geographical RSV trends.  
 
Laboratory diagnosis and clinical management 
By performing laboratory testing we can elucidate the aetiology of infection. 
The information can be used to prevent further infection in children at risk, 
for example by isolating RSV-infected infants at the neonatal care unit. Recent 
advances in laboratory techniques have provided more sensitive methods of 
detection in comparison to “gold standard” detection methods as virus culture. 
With new methods such as real-time PCR, diagnosis and the quality of 
surveillance are improved. However, our results presented in Chapter 7, 
provided a very high proportion of positive specimens (96%) and in about half 
of the children more than one pathogen was detected. This may indicate that 
the PCR may have picked up irrelevant infections for the clinical diagnosis and 
makes it difficult to determine which pathogen was the main cause of the 
respiratory illness. 
 
Although antibiotics have little or no benefit for colds and upper respiratory 
tract infections, these conditions account for a sizable proportion of antibiotic 
prescriptions.14 It has been hypothesized that quick laboratory tests results 
presenting a viral cause of the illness may lead to a reduction in antibiotic use. 
A number of studies have investigated the effect of rapid diagnostic tests on 
antibiotic use, but the results are inconclusive15-19; it may be that different 
effects are observed for different age groups and are related to the severity of 
illness. One difficulty in the hypothesis is that detection of a virus does not 
exclude the presence of a bacterial pathogen. For example studies of autopsy 
specimens have shown that 22 (29%) of the 77 patients attributed to pandemic 
influenza A (H1N1) 2009 virus had molecular evidence of co-infection with an 
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identified bacteria, including 10 persons infected by Streptococcus 
Pneumoniae.20 Therefore, in the diagnosis of respiratory illness it is important 
to test for both viral and bacterial pathogens. 
 
Vaccination 
Currently, no licensed RSV vaccine is available. Several factors have interfered 
with the development of an RSV vaccine. Firstly, infants who are at greatest 
risk of severe disease have a weak immune response. In addition, circulating 
maternally derived antibody may interfere with the immune response of the 
infant. Another important point is related to the testing of a formalin-
inactivated RSV vaccine in infants and children in the 1960s. The vaccine did 
not protect against infection and was associated with an increased risk of 
severe RSV disease when some of the vaccinated children became naturally 
infected.  
 
Two types of candidate RSV vaccines are being evaluated in humans: live 
attenuated vaccines and sub-unit vaccines. An RSV immunization program may 
need to include different vaccines for the different target groups such as 
infants in the first year of life, expectant mothers (so the mother will pass 
immunity to her baby), and high risk groups.21 Maternal vaccination may be an 
interesting strategy and has the potential for preventing RSV disease in early 
infancy. However, for safety reasons, researchers have intuitively been 
reluctant to administer an RSV vaccine to pregnant women.22  
 
In the light of a future vaccine, surveillance of RSV and the application of 
sensitive diagnostic methods are highly relevant. There are three important 
variables in designing efficacy trials: 1) age at vaccination, 2) clinical 
endpoints and 3) laboratory diagnosis. Age-specific rates of acute respiratory 
illness, lower respiratory tract infection and hospitalization may be used as 
clinical endpoints for a vaccine efficacy trial.23  
 
 
Recommendations for future research 
 
Currently, aggregated data form the basis of the surveillance. Limited data is 
available on the number of hospitalised patients and number of deaths. Quality 
of surveillance would improve if information on related illnesses, antibiotic 
use, hospitalisation etc. are collected. There are two points that need 
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attention to accomplish this: firstly case-based information derived from 
patient consultation and investigation should be made available. This however 
may interfere with confidentiality and ethical issues8. Secondly, the required 
surveillance data (ILI, laboratory diagnosis, hospitalisation, treatment, 
underlying disease) originate from separate sources. Therefore, we would 
recommend to link information between the different sources of data. The 
power of surveillance would greatly be enhanced by linking different data 
sources and establishing a fully integrated surveillance model from clinical 
diagnosis to hospitalisation. With modern information technologies this 
becomes more feasible. 
 
Within general practice, consultations for acute respiratory infection are 
common. In children 0-4 years old, infection by RSV is probably the major 
cause of acute bronchiolitis; in the elderly RSV can also cause a significant 
burden24,25, but limited data are available on the role of RSV in hospital 
admissions and deaths in the elderly. The highest proportions of respiratory 
admissions are limited to the young and old, and respiratory death are limited 
almost exclusively to the elderly8. Therefore, it is important to monitor 
respiratory illness in all age groups in both the community and the hospital 
setting. Implementing surveillance in the frail elderly in nursing homes could 
be a major step forward in improving surveillance. For future research we 
would recommend to perform a prospective cohort study to investigate the 
impact of respiratory pathogens, including RSV, in a nursing home setting and 
investigate viral shedding in elderly patients. This will provide more insight in 
the incidence and the respiratory burden in general in this population. 
 
In the United States, the New Vaccine Surveillance Network was established in 
1999 to evaluate the impact on new vaccines and vaccine policies through 
active sentinel surveillance. At three medical centers population-based 
inpatient and enhanced outpatient surveillance for vaccine-preventable 
diseases is conducted. The program complements existing surveillance 
programs for vaccine-preventable diseases by conducting seasonal active 
population-based surveillance for hospitalizations associated with acute 
respiratory illness.26 A similar network could be implemented in Europe, with 
taking the influenza surveillance presented in this thesis as framework. 
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Recent developments in surveillance indicate that also syndromic surveillance 
can be used to detect respiratory virus activity.27,28 For sampling of patients, 
self-sampling may be a good alternative, as it seems a feasible method of 
enhancing community-based surveillance programmes for detection of 
influenza.28 In addition internet-based monitoring has been performed in some 
European countries and showed that reliable data can be collected.29 All these 
types of data can be used to further enhance the surveillance of respiratory 
pathogens. 
 
 
Conclusions 
 
The importance of RSV surveillance needs to be better recognised. Information 
derived from surveillance can be used to understand outbreaks and identify 
causative pathogens and the extent of spread into the population. 
 
With the research presented in this thesis, we have demonstrated that the 
methods of surveillance have been improved; many countries have started 
reporting data on RSV, and data were reported timely. For the Netherlands, 
we have found a regular onset of RSV activity around week 44 and a peak over 
the Christmas holidays. A regional surveillance of RSV would be useful to 
develop in European countries, as this would help in defining the timing of 
palivizumab prophylaxis. Furthermore, we have demonstrated that many 
countries use molecular assays for the detection of RSV and a good 
performance was observed for nested and real-time PCR in particular. Finally, 
multiple respiratory specimens were detected in infants during primary 
respiratory infection. Nasopharyngeal aspirates were superior to nasal swabs in 
terms of sensitivity for RSV and rhinovirus detection. 
 
The findings presented in this thesis provide reference to further establish 
surveillance of RSV on both a regional and European level. RSV surveillance is 
relevant for providing knowledge on “who” is infected and “when”, and will 
provide useful information for the timing of administration of palivizumab. In 
addition, in the light of a future vaccine, fully integrated surveillance data -
from clinical diagnosis to hospitalisation - is important and may be used to 
assess vaccine efficacy. 
 
136 
General discussion 
References 
 
1. Meerhoff TJ, Meijer A, Paget WJ. Methods for sentinel virological surveillance of influenza 
in Europe - an 18-country survey. Euro. Surveill 2004; 9: 1-4. 
2. Meerhoff TJ, Fleming D, Smith A, Mosnier A, Gageldonk-Lafeber AB, Paget WJ. 
Surveillance recommendations based on an exploratory analysis of respiratory syncytial 
virus reports derived from the European Influenza Surveillance System. BMC. Infect. Dis. 
2006; 6: 128. 
3. Meerhoff TJ, Mosnier A, Schellevis F, Paget WJ. Progress in the surveillance of respiratory 
syncytial virus (RSV) in Europe: 2001-2008. Euro. Surveill 2009; 14. 
4. Meerhoff TJ, MacKay WG, Meijer A, Paget WJ, Niesters HG, Kimpen JL, Schellevis F. The 
impact of laboratory characteristics on molecular detection of respiratory syncytial virus 
in a European multicentre quality control study. Clin. Microbiol. Infect. 2008; 14: 1173-
1176. 
5. Last JM. A dictionary of epidemiology, Fourth Edition ed. Oxford University Press; 2001. 
6. Aguilera JF, Paget WJ, Mosnier A, Heijnen ML, Uphoff H, van d, V, Vega T, Watson JM. 
Heterogeneous case definitions used for the surveillance of influenza in Europe. Eur. J. 
Epidemiol. 2003; 18: 751-754. 
7. Meury S, Zeller S, Heininger U. Comparison of clinical characteristics of influenza and 
respiratory syncytial virus infection in hospitalised children and adolescents. Eur. J. 
Pediatr. 2004; 163: 359-363. 
8. Health Protection Agency. A Winter's Tale - Coming to terms with winter respiratory 
illnesses. 2005.  Available at: 
http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1196942154241?p=
1249920576104.  
9. Paget WJ, Meerhoff TJ, Meijer A. Epidemiological and virological assessment of influenza 
activity in Europe during the 2003-2004 season. Euro. Surveill 2005; 10: 107-111. 
10. Meijer A, Meerhoff TJ, Meuwissen LE, van d, V, Paget WJ. Epidemiological and virological 
assessment of influenza activity in Europe during the winter 2005-2006. Euro. Surveill 
2007; 12: E11-E12. 
11. Snacken R, Manuguerra JC, Taylor P. European Influenza Surveillance Scheme on the 
Internet. Methods Inf. Med. 1998; 37: 266-270. 
12.  Respiratory Syncytial virus - Florida department of Health. 2009.  Available at: 
http://www.doh.state.fl.us/disease_ctrl/epi/RSV/rsv.htm 
13.  Brief report: respiratory syncytial virus activity--United States, July 2006-November 
2007. MMWR Morb Mortal Wkly Rep 2007; 56: 1263-1265. 
14. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper 
respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 
278: 901-904. 
15. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid diagnosis 
of influenza on physician decision-making and patient management in the pediatric 
emergency department: results of a randomized, prospective, controlled trial. Pediatrics 
2003; 112: 363-367. 
137 
Chapter 8 
16. Jennings LC, Skopnik H, Burckhardt I, Hribar I, Del Piero L, Deichmann KA. Effect of rapid 
influenza testing on the clinical management of paediatric influenza. Influenza. Other 
Respi. Viruses. 2009; 3: 91-98. 
17. Sharma V, Dowd MD, Slaughter AJ, Simon SD. Effect of rapid diagnosis of influenza virus 
type a on the emergency department management of febrile infants and toddlers. Arch 
Pediatr Adolesc Med 2002; 156: 41-43. 
18. Doan QH, Kissoon N, Dobson S, Whitehouse S, Cochrane D, Schmidt B, Thomas E. A 
randomized, controlled trial of the impact of early and rapid diagnosis of viral infections 
in children brought to an emergency department with febrile respiratory tract illnesses. J 
Pediatr 2009; 154: 91-95. 
19. Oosterheert JJ, van Loon AM, Schuurman R, Hoepelman AI, Hak E, Thijsen S, Nossent G, 
Schneider MM, Hustinx WM, Bonten MJ. Impact of rapid detection of viral and atypical 
bacterial pathogens by real-time polymerase chain reaction for patients with lower 
respiratory tract infection. Clin Infect Dis 2005; 41: 1438-1444. 
20. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic 
influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009; 
58: 1071-1074. 
21. Greenberg HB, Piedra PA. Immunization against viral respiratory disease: a review. 
Pediatr Infect Dis J 2004; 23: S254-S261. 
22. Faber TE, Kimpen JL, Bont LJ. Respiratory syncytial virus bronchiolitis: prevention and 
treatment. Expert Opin Pharmacother 2008; 9: 2451-2458. 
23. Lee MS, Walker RE, Mendelman PM. Medical burden of respiratory syncytial virus and 
parainfluenza virus type 3 infection among US children. Implications for design of vaccine 
trials. Hum Vaccin. 2005; 1: 6-11. 
24. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert. 
Rev. Vaccines. 2008; 7: 249-258. 
25.  Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Influenza- and respiratory 
syncytial virus-associated mortality and hospitalisations. Eur. Respir. J. 2007; 30: 1158-
1166. 
26. Centers for Disease Control and Prevention - RSV surveillance. 2009. 
http://www.cdc.gov/rsv/research/us-surveillance.html  
27. van den Wijngaard C, van Asten L, van Pelt W, Nagelkerke NJ, Verheij R, de Neeling AJ, 
Dekkers A, van der Sande MA, van Vliet H, Koopmans MP. Validation of syndromic 
surveillance for respiratory pathogen activity. Emerg Infect Dis 2008; 14: 917-925. 
28. Cooper DL, Smith GE, Chinemana F, Joseph C, Loveridge P, Sebastionpillai P, Gerard E, 
Zambon M. Linking syndromic surveillance with virological self-sampling. Epidemiol Infect 
2008; 136: 222-224. 
29. Marquet RL, Bartelds AI, van Noort SP, Koppeschaar CE, Paget J, Schellevis FG, van der 
ZJ. Internet-based monitoring of influenza-like illness (ILI) in the general population of 
the Netherlands during the 2003-2004 influenza season. BMC Public Health 2006; 6: 242. 
 
138 
  
 
 
 
 
 
Summary 
 
139 
  
140 
Summary 
Summary 
 
Chapter 1 is a general introduction to this thesis. Respiratory syncytial virus 
(RSV) causes a substantial burden in particular in the very young and old. The 
spectrum of clinical disease ranges from mild upper respiratory tract illness, 
otitis media, croup to apnea in premature infants, pneumonia and 
bronchiolitis. In Europe, RSV accounts for 42-45% of hospitals admissions for 
lower respiratory tract infections in children younger than two years of age. At 
present there is no licensed RSV vaccine. Profylactic use of neutralizing 
antibody is available. Monthly administration of palivizumab reduces the risk of 
hospitalisation in premature infants and infants with chronic lung disease or 
congenital heart disease. Currently, rapid and sensitive molecular techniques 
for RSV diagnosis are available. With surveillance of RSV, outbreaks can be 
rapidly detected. In addition, the longitudinal surveillance data can be used to 
measure the impact of palivizumab prophylaxis and effectiveness of a future 
RSV vaccine. In this thesis we aimed to improve surveillance and diagnostic 
methods of respiratory syncytial virus in Europe. In Chapter 2 we have 
assessed the comparability of virological data for the detection of influenza in 
countries in Europe and investigated which countries collect RSV data. The 
type of respiratory specimen and the transport conditions were similar. The 
diagnostic methods were diverse, and PCR was more often carried out in 
countries in Western Europe. In Chapter 3 we assessed whether data on RSV 
collected by a European influenza surveillance network could be used to build 
an RSV surveillance system in Europe. Data on RSV from France, the 
Netherlands, England and Scotland were used. The data were entered timely. 
RSV contributed noticeably to influenza-like illness. Recommendations for RSV 
surveillance were formulated: 1) Specimens collected as part of an influenza 
surveillance program should also be tested for RSV; 2) Both combined nose-
throat swabs and nasopharyngeal aspirates are acceptable for RSV diagnostics; 
3) The application of molecular techniques such as real-time PCR in the 
diagnosis of respiratory disease has been demonstrated and we advocate this 
technique for RSV detection; 4) Further develop standardized methods and 
laboratory techniques; 5) Consider the development of a sentinel approach of 
representative hospitals; 6) Integration of RSV surveillance in countries joining 
the surveillance system alongside influenza. Following the surveillance 
recommendations, we presented the progress over seven years (2001-2008) 
(Chapter 4). By 2008, progress was made for four out of six recommendations: 
the number of European countries testing specimens for RSV increased from six 
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to fourteen; nose and/or throat swabs were generally used for detection of 
influenza and RSV; a total of 25 laboratories performed molecular testing for 
diagnosis and participated in a quality control assessment for RSV with an 
overall good performance; four of the ten countries that joined EISS in 2004 
started reporting RSV detections in addition to influenza in the period 2004-8. 
Limited progress was achieved for standardising methods and the development 
of a sentinel surveillance system of representative hospitals. In Chapter 5 we 
have described the seasonal variation in RSV activity and investigated which 
meteorological variables are related to RSV outbreaks for different time lags. 
Time lags up to 4 weeks were included to assess a possible delayed weather 
effect in relation to RSV activity. We have found that the onset of RSV activity 
occurred around week 44 and activity peaked around week 52. Relative 
humidity was positively associated with RSV activity for all time lags, 
indicating more RSV when relative humidity increased. Minimum temperature 
was negatively associated with RSV activity and cloud cover was positively 
related with RSV activity. Relative humidity, minimum temperature, and cloud 
cover are important predictors of RSV activity in the Netherlands, with the 
effect of relative humidity being most consistent. In Chapter 6 the laboratory 
performance of nucleic acid amplification techniques for respiratory syncytial 
virus (RSV) diagnosis was investigated in 25 laboratories across Europe. In 
addition we explored what factors were related to the diagnostic performance. 
The overall sensitivity for all laboratories was 88% (n=25; range 50-100). A 
correct score of 93% (range 70-100) was observed for laboratories performing 
in-house real-time PCR or nested PCR. Multilevel analysis showed that the type 
of assay (nested or real-time PCR vs. commercial test) was a significant factor 
(OR=8.39; CI95% 1.91-36.78) in predicting a correct result. The results for this 
external quality control study showed that the overall performance of 
laboratories for RSV diagnosis in Europe is good and that real-time PCR is 
preferably used for RSV diagnostics. In Chapter 7 we present the detection of 
respiratory viruses in infants during primary respiratory illness, investigate the 
sensitivity of nasal swabs and nasopharyngeal aspirates and assess whether 
patient characteristics and viral load played a role in the sensitivity. Paired 
nasopharyngeal aspirates and nasal swabs were collected in 98 infants. 
Rhinovirus (n=67) and respiratory syncytial virus (n=39) were most frequently 
detected. Co-infection occurred in 48% (n=45) of the infants. The sensitivity of 
the nasal swab was lower than the nasopharyngeal aspirate in particular for 
respiratory syncytial virus (51% vs. 100%) and rhinovirus (75% vs. 97%). 
Sensitivity of the nasal swab was strongly determined by the cycle threshold 
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value (p<0.001). Sensitivity of the swab for respiratory syncytial virus, but not 
rhinovirus, was 100% in children with severe symptoms (score≥11). It is 
concluded that for community based studies and surveillance purposes the 
nasal swab can be used, though the sensitivity is lower than the aspirate in 
particular for the detection of mild cases of RSV infection. Finally, in Chapter 
8, the results of the earlier chapters were summarised and discussed and the 
implications and recommendations for future research were formulated. RSV 
surveillance may be used to support clinical decision making for prophylaxis in 
premature infants and the data obtained through RSV surveillance has been 
useful in understanding the seasonal and geographical RSV trends. The findings 
of this thesis will provide reference to further establish surveillance of RSV on 
both a regional and European level. RSV surveillance is relevant for providing 
knowledge on “who” is infected and “when”, and will provide useful 
information for the timing of administration of palivizumab. In addition, in the 
light of a future vaccine, fully integrated surveillance data - from clinical 
diagnosis to hospitalisation - is important and may be used to assess vaccine 
efficacy. 
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In hoofdstuk 1 wordt een algemene inleiding gegeven van dit proefschrift, 
getiteld Respiratoir syncytieel virus: het verbeteren van surveillance en 
diagnostiek in Europa. Het respiratoir syncytieel virus (RS-virus) infecteert de 
luchtwegen en veroorzaakt een aanzienlijke ziektelast in voornamelijk jonge 
kinderen en ouderen. Het klinische beeld varieert van milde bovenste 
luchtweginfectie, otitis media, kroep en apneu in prematuren, tot 
longontsteking en bronchiolitis. Een groot deel van de ziekenhuisopnamen voor 
lagere luchtweginfecties in kinderen onder de twee jaar is gerelateerd aan 
infectie met het RS-virus. Tot op heden is er geen vaccin tegen RS-virus 
infectie. Wel is profylactisch gebruik van neutraliserende antilichamen 
(palivizumab) beschikbaar. De maandelijkse toediening van palivizumab 
vermindert het risico op ziekenhuisopname in prematuren en kinderen met een 
chronische longaandoening of een aangeboren hartafwijking. Tegenwoordig 
zijn er snelle en zeer gevoelige moleculaire technieken beschikbaar voor het 
aantonen van het RS-virus. Door het monitoren van het RS-virus kunnen 
uitbraken van dit virus snel worden gedetecteerd. Daarnaast kan longitudinale 
surveillance data worden gebruikt om het effect van palivizumab profylaxe te 
meten. Op langere termijn zal surveillance data ook nuttig zijn om inzicht te 
krijgen in de effectiviteit van een toekomstig vaccin. Het doel van dit 
proefschrift is het verbeteren van surveillance en diagnostische methoden voor 
detectie van het RS-virus in Europa. In Hoofdstuk 2 is onderzocht hoe 
vergelijkbaar de influenza dataverzameling is in landen binnen Europa. Tevens 
hebben we onderzocht welke landen testen uitvoeren om het RS-virus en 
andere respiratoire pathogenen te detecteren. In de meeste landen werden 
neus en/of keelwatten afgenomen. De transportomstandigheden waren 
vergelijkbaar. Verschillende diagnostische methoden werden gebruikt; 
polymerase keten reactie (PCR) werd vooral gebruikt in de landen in West-
Europa. In Hoofdstuk 3 is onderzocht of RS-virus data verzameld via een 
Europees influenza surveillance netwerk bruikbaar was voor het opzetten van 
RS-virus surveillance. RS-virus detecties in Frankrijk, Nederland, Engeland en 
Schotland werden beschreven. De data werden tijdig ingevoerd. Het RS-virus 
werd regelmatig aangetoond in patiënten met een griepachtig ziektebeeld. 
Tevens werden de volgende aanbevelingen gedaan: 
1. Neus- en keelwatten die worden verzameld ten behoeve van influenza 
surveillance zouden ook getest moeten op aanwezigheid van het RS-virus; 
2. Zowel gecombineerde neus-keelwatten en nasopharyngeale aspiraten zijn 
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acceptabel voor detectie van het RS-virus; 
3. Het gebruik van moleculaire technieken zoals real-time wordt aanbevolen 
voor RS-virus detectie; 
4. Verdere ontwikkeling van gestandaardiseerde methoden en laboratorium-
technieken; 
5. De ontwikkeling van een “sentinel” benadering van representatieve zieken-
huizen; 
6. Integratie van RS-virus surveillance naast influenza in nieuwe deelnemende 
landen binnen het influenza surveillance systeem. 
De vooruitgang van RS-virus surveillance binnen het influenza surveillance 
systeem over een periode van 7 jaar (2001-2008) is beschreven in Hoofdstuk 4. 
Er is vooruitgang geboekt voor vier van de zes aanbevelingen gepresenteerd in 
Hoofdstuk 3: 1) het aantal Europese landen dat neus- en/of keelwatten testte 
voor het RS-virus nam toe van zes naar veertien; 2) neus- en/of keelwatten 
werden doorgaans gebruikt voor de detectie van influenza en het RS-virus; 3)  
25 laboratoria hebben deelgenomen aan een kwaliteitscontrole voor 
moleculaire technieken. De laboratoria hadden een goede score; 4) vier van de 
10 nieuwe landen rapporteerden RS-virus detecties naast influenza virus 
detecties in de periode 2004-2008. Beperkte vooruitgang was geboekt in het 
standaardiseren van methoden en de ontwikkeling van een “sentinel” 
surveillance systeem van representatieve ziekenhuizen. In Hoofdstuk 5 is de 
seizoensvariatie van het RS-virus beschreven en we hebben onderzocht welke 
meteorologische factoren zijn gerelateerd aan RS-virus activiteit. Om te 
onderzoeken of er een mogelijk verlaat effect van weersfactoren was op RS-
virus activiteit zijn verschillende tijdsmomenten meegenomen in de analyses, 
deze varieerde van 0 tot 4 weken. De start van RS-virus activiteit was rond 
week 44 en de activiteit was het hoogst rond week 52. De relatieve 
vochtigheid was positief geassocieerd met RS-virus activiteit, dit houdt in dat 
bij er meer RS-virus detecties waren bij een hogere relatieve vochtigheid. 
Minimum temperatuur was negatief geassocieerd met RS-virus activiteit - 
oftewel er waren meer RS-virus detecties bij een lagere temperatuur. Tevens 
was de bewolkingsgraad positief geassocieerd met RS-virus activiteit. Relatieve 
vochtigheid, minimum temperatuur, en de bewolkingsgraad zijn belangrijke 
predictoren van RS-virus activiteit in Nederland. In Hoofdstuk 6 is voor 25 
laboratoria in Europa de kwaliteit van de nieuwste moleculaire technieken 
voor de detectie van het RS-virus onderzocht. Daarnaast hebben we 
onderzocht welke factoren gerelateerd waren met de sensitiviteit van de test. 
De sensitiviteit voor testen voor alle laboratoria was 88% (n=25). Een correcte 
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score van 93% vonden we voor laboratoria die een in-house real-time PCR of 
nested PCR gebruikten. Multilevel analyse liet zien dat het type test (nested of 
real-time PCR vs. commerciële test) een significante factor was (OR=8.39; CI95% 
1.91-36.78) in het voorspellen van een correct resultaat. De resultaten gaven 
aan dat de sensitiviteit voor RS-virus diagnose in Europa goed is en dat real-
time PCR bij voorkeur wordt gebruikt voor RS-virus diagnostiek. In Hoofdstuk 7 
wordt de detectie van respiratoire virussen gepresenteerd voor zuigelingen 
tijdens de eerste respiratoire infectie en is de sensitiviteit van neuswatten and 
nasopharyngeale aspiraten onderzocht. Tevens is gekeken naar de rol van 
patiënt eigenschappen en hoeveelheid virus (“virale load”) voor de 
sensitiviteit. Gepaarde nasopharyngeale aspiraten en neuswatten werden 
afgenomen bij 98 zuigelingen. Rhinovirus (n=67) en RS-virus (n=39) werden het 
meest frequent gedetecteerd. Meer dan 1 pathogeen werd gedetecteerd in 48% 
(n=45) van de kinderen. De sensitiviteit van de neuswat was lager dan het 
nasopharyngeale aspiraat, dit was meest duidelijk voor de detectie van het RS-
virus (51% vs. 100%) en rhinovirus (75% vs. 97%). De sensitiviteit van de test 
voor de afgenomen neuswat was sterk gerelateerd met de Ct waarde (Cycle 
threshold) (p<0.001). Voor epidemiologische studies en surveillance doeleinden 
kan de neuswat worden gebruikt. Een nadeel is echter dat de sensitiviteit van 
de test lager is dan bij het aspiraat, dit speelt vooral een rol bij mildere 
infecties van RS-virus. In Hoofdstuk 8 ten slotte, worden de resultaten van 
eerdere hoofdstukken samengevat. RS-virus surveillance kan gebruikt worden 
ter ondersteuning van klinische besluitvorming voor profylaxe in premature 
zuigelingen. Tevens helpt RS-virus surveillance bij het beter begrijpen van 
geografische trends van respiratoire infecties. De bevindingen in dit 
proefschrift zorgen voor aanknopingspunten om de surveillance verder te 
ontwikkelen op zowel regionaal als Europees niveau. RS-virus surveillance is 
relevant voor kennis over “wie” geïnfecteerd is en “wanneer”, en geeft 
nuttige informatie wat de beste tijd is voor het toedienen van palivizumab. 
Tevens is een volledig geïntegreerd surveillance systeem - van klinische 
diagnose tot ziekenhuisopname - van groot belang en kan in de toekomst nuttig 
zijn voor effectiviteitonderzoek van een vaccin tegen het RS-virus. 
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Het is zover, mijn proefschrift is af. 
Het begon allemaal ongeveer zes jaar geleden met de vraag of ik zou willen 
promoveren. Ik werkte toen aan het influenza surveillance project (EISS), 
waarvan het NIVEL destijds het coördinatie centrum was. Vanuit de influenza 
surveillance was er een toenemende interesse voor het RS-virus. Vandaar dat 
ik verschillende onderzoeken heb uitgevoerd welke worden beschreven in dit 
proefschrift. Ik ben het NIVEL dankbaar dat ik de mogelijkheid heb gekregen 
dit onderzoek naast mijn reguliere influenza werkzaamheden te doen en dan 
ook nog in deeltijd. Het schrijven is een bijzonder en leerzaam proces. Ik 
vergelijk het schrijven van een artikel wel eens met beeldhouwen. Je blijft 
eraan schaven en je moet regelmatig even afstand nemen voordat je verder 
kunt. En… veel oefenen baart kunst. 
 
Nu heb ik dit proefschrift niet alleen geschreven. Vele mensen hebben mee-
gedacht en meegeschreven. Graag wil ik deze mensen bedanken. 
 
Als eerste bedank ik mijn promotor François Schellevis voor de prettige samen-
werking de afgelopen jaren en de goede ideeën. Het regelmatige overleg met 
jou was altijd nuttig en stapje voor stapje kwam ik een stukje dichterbij de 
voltooiing van dit proefschrift. Ook wil ik graag Jan Kimpen, mijn tweede 
promotor bedanken voor het enthousiasme en de fijne samenwerking. Ook al 
ben je in een wat latere fase van het traject betrokken bij het onderzoek, het 
overleg was altijd prettig en inspirerend. Bedankt voor je tijd en aandacht. 
 
John Paget, als dagelijks begeleider was jij het best op de hoogte van mijn 
reilen en zeilen. Ik wil je bedanken voor de fijne samenwerking in de af-
gelopen jaren. Bedankt voor je tijd, energie en goede suggesties voor het 
verbeteren van artikelen. Ik heb veel van je geleerd. 
 
153 
Dankwoord 
De leden van de leescommissie bedank ik hartelijk voor het beoordelen van het 
manuscript: dr. Bont, prof. dr. Vandenbroucke-Grauls, dr. Fleming, prof. dr. 
Koopmans, prof. dr. Twisk en prof. dr. Van de Velden.  
 
Thanks to the participants of the EISS RSV Task Group for all your efforts, time 
and energy! And thanks to all doctors, epidemiologists and virologists for your 
work. Without your effort surveillance would not be possible. 
 
Dan een woord van dank aan de alle co-auteurs. Many thanks to all of you that 
have contributed to one or more papers. 
 
Ook wil ik mijn paranimfen, mijn broer Gideon en Eveline Veenhof, bedanken 
dat ze naast mij staan bij de verdediging van mijn proefschrift. 
 
Ik wil graag mijn collega’s van het NIVEL bedanken voor hun belangstelling en 
gezelligheid. In het bijzonder alle mensen die deel uitmaakten van het EISS-
team. Ik wil Peter Spreeuwenberg bedanken voor de statistische adviezen en 
hulp bij het uitvoeren van analyses, en Mark Nielen voor het uitvoeren van het 
multilevel analyse voor het artikel over de kwaliteit van de laboratorium 
testen. Marina van Geelkerken heeft de lay-out van dit proefschrift perfect 
verzorgd. Mijn dank hiervoor. En Richard van Kruijsdijk dank voor het maken 
van de mooie buitenkant van mijn proefschrift! 
 
Er zijn in de afgelopen heel wat kamergenoten voorbij gekomen. Als vast 
baken de laatste jaren – Christel - ik wil je graag bedanken voor de gezellig-
heid, goede adviezen en de heerlijke kopjes thee. Succes met het schrijven 
van jouw proefschrift! Ook Carlijn bedankt voor de gezelligheid en zomerse 
lunches buiten in de tuin. Ik heb geboft met zulke fijne kamergenoten! 
 
Lieve Marije, Judith en Eef, ik vind het superfijn dat we elkaar nog steeds zien 
sinds de studie Medische Biologie. Bedankt voor jullie luisterend oor, 
gezelligheid en medeleven. Ik hoop dat we nog heel lang vrienden blijven! 
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Dank aan alle (schoon)familie, vrienden en bekenden. Voor velen van jullie 
was het niet zo duidelijk waar ik nu mee bezig was de afgelopen jaren; ja.. 
iets over griep en het RS-virus. Lieve mam, pap, Vanessa, Gideon en Melchior, 
jullie vormen de basis van wie ik nu ben. Dank voor jullie aandacht en 
welkome afleiding van het werk. Het is fijn te weten dat jullie er zijn en altijd 
voor me klaar staan.  
 
Dan nu het thuisfront, liefste Pedro, Arvid en Tibor. Het zijn drukke jaren 
geweest; het was soms een kunst om de aandacht goed te verdelen. Lieve 
Pedro, ik wil je bedanken voor je vertrouwen en onvoorwaardelijke liefde. 
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